Immunotherapy of Human Cancer

  • Evan M. Hersh
  • G. M. Mavligit
  • J. U. Gutterman
  • S. P. Richman
Part of the Cancer book series (C, volume 6)


The efficacy of the conventional modalities of cancer treatment—surgery, radiotherapy, and chemotherapy—has been reasonably well defined. There is also sufficient experience to permit one to predict the nature of future improvements in efficacy for these conventional modalities. For surgery, it is likely that the limit of efficacy has been reached, and while surgery can effectively cure a proportion of patients with apparent local disease, it is clear that disseminated, microscopic tumor deposits are present in at least half the operable cases at the time of surgery, ultimately eventuating in metastatic disease. A limited but important additional role for surgery will be the debulking of metastatic disease in an attempt to reduce the tumor burden and thus to improve the efficacy of subsequent systemic treatment with chemotherapy, immunotherapy, and other possible approaches.


Transfer Factor Baccillus Calmette Guerin Purify Protein Derivative Adoptive Immunotherapy Remission Duration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alexander, P., and Delorme, E. J., 1971, The use of irradiated immune lymphoid cells for immunotherapy of primary tumors in rats, Israel J. Med. Sci. 7:239.PubMedGoogle Scholar
  2. Alexander, P., and Evans, R., 1971, Endotoxin and double-stranded RNA render macrophages cytotoxic, Nature (London) 232:76.Google Scholar
  3. Alexander, P., Delorme, E. J., Hamilton, L. D. G., et al., 1967, Effect of nucleic acids from immune lymphocytes on rat sarcomata, Nature (London) 213:569.Google Scholar
  4. Alexander, P., Eccles, S., and Gauci, C. L. L., 1976, The significance of macrophages in human and experimental tumors, Ann. N. Y. Acad. Sci. 276:124.PubMedGoogle Scholar
  5. Allison, A. C., Berman, L. D., and Levy, R. H., 1967, Increased tumor induction by adenovirus type 12 in thymectomized mice and mice treated with anti-lymphocyte serum, Nature (London) 125:185.Google Scholar
  6. Amery, W. K., 1976, Double-blind levamisole trial in resectable lung cancer, Ann. N.Y. Acad. Sci. 277:216.Google Scholar
  7. Amiel, J. L., and Berardet, M., 1970, An experimental model of active immunotherapy preceded by cytoreductive chemotherapy, Eur. J. Cancer 6:557.PubMedGoogle Scholar
  8. Anderson, J., Sjöberg, O., and Moller, G., 1972, Mitogens as probes for immunocyte activation and cellular cooperation, Transplant Rev. 11:131.Google Scholar
  9. Bach, J. F., and Dardenne, M., 1973, Studies on thymus products. II. Demonstration and characterization of a circulating thymic hormone, Immunology 25:353.PubMedGoogle Scholar
  10. Bach, J. F., Dardenne, M., Pleau, J. M., et al., 1975, Isolation, biochemical characteristics, and biological activity of a circulating thymic hormone in the mouse and in the human, Ann. N. Y. Acad. Sci. 249:186.PubMedGoogle Scholar
  11. Baldwin, R. W., and Pimm, M. V., 1973a, BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells. Br. J. Cancer 27:48.PubMedGoogle Scholar
  12. Baldwin, R. W., and Pimm, M. V., 1973b, BCG immunotherapy of rat tumors of defined immunogenicity, Natl. Cancer Inst. Monogr. 39:11.PubMedGoogle Scholar
  13. Ballow, M., Dupont, B., and Good, R. A., 1973, Autoimmune hemolytic anemia in Wiscott-Aldrich syndrome during treatment with transfer factor, J. Pediat. 83:772.PubMedGoogle Scholar
  14. Balner, H., and Dersjant, H., 1969, Increased oncogenic eifect of methylcholantherene after treatment with anti-lymphocyte serum, Nature (London) 224:376.Google Scholar
  15. Band, P. R., Jao-King, C., and Urtasun, R. C., 1975, Phase I study of Corynebacterium parvum in patients with solid tumors, Cancer Chemother. Rep. 59:1139.PubMedGoogle Scholar
  16. Bansal, S. C., and Sjögren, H. O., 1972, Counter action of the blocking of cell-mediated tumor immunity by inoculation of unblocking sera and splenectomy: Immunotherapeutic effects on primary polyoma tumors in rats, Int. J. Cancer 9:490.PubMedGoogle Scholar
  17. Bansal, S. C., and Sjörgen, H. O., 1973, Effects of BCG on various facets of the immune response against polyoma tumors in rats, Int. J. Cancer 11:162.PubMedGoogle Scholar
  18. Baram, P., and Condoulis, W., 1970, The in vitro transfer of delayed hypersensitivity to rhesus monkey and human lymphocytes with transfer factor obtained from rhesus monkey peripheral white blood cells, J. Immunol. 104:769.PubMedGoogle Scholar
  19. Baram, P., and Condoulis, W., 1974, Studies on rhesus monkey non-dialyzable and dialyzable transfer factor, Transplantation Proc. 6:209.Google Scholar
  20. Bartlett, G. L., and Zbar, B., 1972, Tumor-specific vaccine containing Mycobacterium bovis and tumor cells: Safety and efficacy, J. Natl. Cancer Inst. 48:1709.PubMedGoogle Scholar
  21. Bartlett, G. L., Zbar, B., and Rapp, H. J., 1972, Suppression of murine tumor growth by immune reaction to the bacillus Calmette Guérin strain of Mycobacterium bovis,J. Natl. Cancer Inst. 48:245.PubMedGoogle Scholar
  22. Basch, R. S., and Goldstein, G., 1975, Antigenic and functional evidence for the in vitro inductive actvity of thymopoietin (thymin) on thymocyte precursors, Ann. N.Y. Acad. Sci. 291:290.Google Scholar
  23. Bast, R. C., Bast, B. S., and Rapp, H. J., 1976, Critical review of previously reported animal studies of tumor immunotherapy with non-specific immunostimulants, Ann. N Y. Acad. Sci. 277:60.PubMedGoogle Scholar
  24. Bekesi, J. G., and Holland, J. F., 1974, Combined chemotherapy and immunotherapy of transplantable and spontaneous murine leukemia in DBA/2 HA and AKR mice, Recent Results Cancer Res. 47:357.Google Scholar
  25. Bekesi, J. G., Roboz, J. P., and Holland, J. F., 1976, Therapeutic effectiveness of neuraminidase treated tumor cells as an immunogen in man and experimental animals with leukemia, Ann. N. Y. Acad. Sci. 277:313.PubMedGoogle Scholar
  26. Bekierkunst, A., Levij, I. S., and Yarkoni, E., et al., 1971, Suppression of urethane-induced lung adenomas in mice treated with trehalose-6,6-dimycolate (core factor) and living bacillus Calmette Guérin, Science 174:1240.PubMedGoogle Scholar
  27. Ben-Efraim, S., Constantini-Sourojon, M., and Weiss, D. W., 1973, Potentiation and modulation of the immune response of guinea pigs to poorly immunogenic protein haptene conjugates by pre-treatment with the MER fraction of attenuated tubercle bacilli, Cell. Immunol. 7:370.PubMedGoogle Scholar
  28. Ben-Efraim, S., Teitelbaum, R., Ophir, R., et al., 1974, Non-specific modulation of immunological responsiveness in guinea pigs and mice by the tumor protective methanol extraction residue (MER) mycobacterial fraction, Israel J. Med. Sci. 10:972.Google Scholar
  29. Ben-Efraim, S., Ophir, R., Teitelbaum, R., et al., 1977, Effect of the MER tubercle bacillus fraction on the tolerance threshold of mice to T-independent polysaccharide antigens, submitted for publication.Google Scholar
  30. Benjamini, E., Theilen, G. H., Torten, M., et al., 1976, Tumor vaccines for immunotherapy of canine lymphosarcoma, Ann. N. Y. Acad. Sci. 277:305.PubMedGoogle Scholar
  31. Bensa, J. C., Foure, J., Martin, H., et al., 1976, Levamisole in angioimmunoblastic lymphadenopathy, Lancet 1:1081.PubMedGoogle Scholar
  32. Beretta, A., 977, Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as adjuvant to surgery, in: Immunotherapy of Cancer: Present Status of Trial in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  33. Berger, D. R., Vetto, R. M., and Malley, A., 1972, Transfer factor from guinea pigs sensitive to dinitrochlorobenzene: Absence of supra-antigen properties, Science 185:1473.Google Scholar
  34. Berger, F. M., Fukui, G. M., Ludwig, B. J., et al., 1969, Increased host resistance to infection solicited by lipopolysaccharides from Brucella abortus,Proc. Soc. Exp. Biol. 131:1376.PubMedGoogle Scholar
  35. Black, M. M., Spear, S. P., and Opler, S. R., 1956, Structural representations of tumor host relationship in mammary carcinoma: Biologic and prognostic significance, Amer. J. Clin. Pathol. 26:250.Google Scholar
  36. Bloom, B. R., 1969, Elaboration of effector molecules by activated lymphocytes, in: Mediators of Cellular Immunity (H. S. Lawrence and M. Landy, eds.), pp. 249–319, Academic Press, New York.Google Scholar
  37. Bluming, A. Z., Vogel, C. L., Ziegler, J. L., et al., 1972, Immunological effects of BCG in malignant melanoma: Two modes of administration compared, Ann. Intern. Med. 76:405.PubMedGoogle Scholar
  38. Bomford, R., and Olivotto, M., 1974, The mechanism of inhibition by Corynebacteriumparvum of the growth of lung nodules from intravenously injected tumor cells, Int. J. Cancer 14:226.PubMedGoogle Scholar
  39. Borberg, H., Oettgen, H. F., and Choudry, K., 1972, Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors, Int. J. Cancer 10:539.PubMedGoogle Scholar
  40. Borsos, T., Bast, R. C., O’Hanian, S. H., et al., 1976, Induction of tumor immunity by intratumoral chemotherapy, Ann. N. Y. Acad. Sci. 276:560.Google Scholar
  41. Bortin, M. M., Rimm, A. A., and Saltzstein, E. C., 1973, Graft versus leukemia: Quantification of adoptive immunotherapy in murine leukemia, Science 179:811.PubMedGoogle Scholar
  42. Brandes, L. J., Galton, D. A. G., and Wiltsha, W., 1971, New approaches to immunotherapy of melanoma, Lancet 2:293.PubMedGoogle Scholar
  43. Branic, M., 1970, Transplantability of leukemia from leukemic mice after irradiation and injection of allogeneic spleen cells, Eur. J. J. Clin. Biol. Res. 15:104.Google Scholar
  44. Braun, W., 1974, Regulatory factors in the immune response, in: Cyclic AMP, Cell. Growth and the Immune Response (W. Braun et al., eds.), pp. 4–23, Springer-Verlag, New York.Google Scholar
  45. Braun, W., Regelson, W., Yajima, Y., et al., 1970, Stimulation of antibody formation by pyran copolymer, Proc. Soc. Exp. Biol. Med. 133:171.PubMedGoogle Scholar
  46. Braun, W., Lichtenstein, L. M., and Parker, C. W., 1974, in: Cyclic AMP, Cell. Growth and the Immune Response, Springer-Verlag, New York.Google Scholar
  47. Brodeur, B. R., and Marigan, T. C., 1974, Suppressive effect of interferon on the humoral immune response to sheep red blood cells in mice, J. Immunol. 113:1319.PubMedGoogle Scholar
  48. Bucana, C., and Hanna, M. G., 1974, Immunoelectron microscopic analysis of surface antigens common to Mycobacterium bovis, BCG and tumor cells, J. Natl. Cancer Inst. 53:1313.PubMedGoogle Scholar
  49. Bullough, W. S., and Laurence, E. B., 1968, Melanocyte chalone and mitotic control in melanomata, Nature (London) 220:137.Google Scholar
  50. Burkitt, D., 1967, Clinical evidence suggesting the development of an immunological response against African lymphoma, in: Treatment of Burkitt’s Tumor (J. H. Burchenal and D. P. Burkitt, eds.), pp. 197–203, Springer-Verlag, New York.Google Scholar
  51. Burnett, F. M., 1970, The concept of immunological surveillance, Prog. Exp. Tumor Res. 13:1.Google Scholar
  52. Byers, V. S., Levin, A. S., Lecam, L., et al., 1976, Tumor-specific transfer factor therapy in osteogenic sarcoma, Ann. N.Y. Acad. Sci. 277:621.PubMedGoogle Scholar
  53. Carswell, E. A., Old, L. J., Kassel, R. L., et al., 1975, An endotoxin-induced serum factor that causes necrosis of tumors, Proc. Natl. Acad. Sci. USA 72:3666.PubMedGoogle Scholar
  54. Catalona, W. J., Tarpley, J. L., Chretien, P. B., et al., 1974, Lymphocyte stimulation in urologic cancer patients, J.Urol. 112:373.PubMedGoogle Scholar
  55. Cater, D. B., and Waldmann, H., 1967, The effects on the growth of PB/8 ascites tumor in C3H, C57, Fl, or C3H mice of lymphocyte preparations from C57 mice injected with PB/8 cells and Freund’s adjuvant, Br. J. Cancer 21:124.PubMedGoogle Scholar
  56. Chee, D. O., and Bodurtha, A. J., 1974, Facilitation and inhibition of B16 melanoma by BCG in vivo and by lymphoid cells from BCG-treated mice in vitro,Int. J. Cancer 14:137.PubMedGoogle Scholar
  57. Cheema, R. A., and Hersh, E. M., 1972, Local tumor immunotherapy with in vitro activated autochthonous lymphocytes, Cancer 29:982.PubMedGoogle Scholar
  58. Chess, L., Levy, M., Schmukler, K., et al., 1972, The effect of synthetic polynucleotides on immunologically induced treated thymidine incorporation, Transplantation 14:748.PubMedGoogle Scholar
  59. Chirigos, M. A., Turner, W., Pierson, J., et al., 1969, Effective anti-viral therapy of two murine leukemias with an interferon-inducing synthetic carboxylate copolymer, Int. J. Cancer 4:267.PubMedGoogle Scholar
  60. Chirigos, M. A., Pierson, J. W., and Fuhrman, F. S., 1974, Effect of tumor load reduction on successful immunostimulation, Proc. Am. Assoc. Cancer Res. 15:116.Google Scholar
  61. Chisari, F. V., Northrup, R. S., and Chen, L. C., 1974, The modulating effect of cholera enterotoxin on the immune response, J. Immunol. 113:729.PubMedGoogle Scholar
  62. Chung, E. B., Zbar, B., and Rapp, H. J., 1973, Tumor regression mediated by Mycobacterium bovis (strain BCG): Effects of isonicotinic acid hydrazide, cortisone acetate, and anti-thymocyte serum, J. Natl. Cancer Inst. 51:241.PubMedGoogle Scholar
  63. Clarkson, B. C., Dowling, M. D., Gee, T. S., et al., 1975, Treatment of acute leukemia in adults, Cancer 36:775.PubMedGoogle Scholar
  64. Cleveland, R. P., Meltzer, M. S., and Zbar, B., 1974, Tumor cytotoxicity in vitro by macrophages from mice infected with Mycobacterium bovis strain BCG, J. Natl. Cancer Inst. 52:1887.PubMedGoogle Scholar
  65. Coley, W. B., 1896, The therapeutic value of the mixed toxins of the Streptococcus of erysipelas and Bacillus prodigiosus in the treatment of inoperable tumors with a report of 160 cases, Amer. J. Med. Sci. 112:251.Google Scholar
  66. Cone, R. E., and Johnson, A. G., 1971, Regulation of the immune system by synthetic polynucleotides: Action on antigen reactive cells of thymic origin, J. Exp. Med. 133:665.PubMedGoogle Scholar
  67. Costanzi, J. J., 1977, Chemotherapy and BCG in the treatment of disseminated malignant melanoma: A Southwest Group Study, In: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  68. Cunningham, T. J., Olson, K. B., Laffin, R., et al., 1969, Treatment of advanced cancer with active immunization, Cancer 24:932.PubMedGoogle Scholar
  69. Cunningham, T. J., Antenann, R., and Paonessa, D., 1976, Adjuvant immuno- and/or chemotherapy with neuraminidase treated autogenous tumor vaccine and bacillus Calmette Guérin for head and neck cancers, Ann. N Y. Acad. Sci. 277:339.PubMedGoogle Scholar
  70. Cunningham, T. J., Schoenfeld, D., Walters, J., et al., 1977, A controlled study of adjuvant therapy (BCG—BCG—DTIC) with stage I and II melanoma, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  71. Currie, G. A., and Bagshawe, K. D., 1970, Active immunotherapy with Corynebacterium parvum and chemotherapy in murine fibrosarcomas, Br. Med. J. 1:541.PubMedGoogle Scholar
  72. Currie, G. A., and McElwain, T. J., 1975, Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: A pilot study, Br. J. Cancer 31:143.PubMedGoogle Scholar
  73. Currie, G. A., Lejeune, F., and Fairley, G. H., 1971, Immunization with irradiated tumor cells and specific lymphocyte cytotoxicity in malignant melanoma, Br. Med. J. 2:305.PubMedGoogle Scholar
  74. Curtis, J. E., Hersh, E. M., and Freireich, E. J., 1969, Transfer of immunity in man with peripheral blood leukocytes (PBL), Proc. Am. Assoc. Cancer Res. 10:17.Google Scholar
  75. Cuttler, S. J., and Heise, H. W., 1969, Efficacy of current treatment methods of cancer of the breast, Cancer 24:1117.Google Scholar
  76. Cuttner, J., Holland, J. F., Bekesi, J. G., et al., 1975, Chemoimmunotherapy of acute myelocytic leukemia, Proc. Am. Soc. Clin. Oncol. 16:264.Google Scholar
  77. Cuttner, J., Bekesi, J. G., and Holland, J. F., 1976, Chemoimmunotherapy of acute leukemia using MER, Proc. Am. Assoc. Cancer Res. 17:196.Google Scholar
  78. Cuttner, J., Glidwell, O., and Holland, J. F., 1977, A comparative study of the value of immunotherapy with MER as adjuvant to induction and two maintenance chemotherapy programs in acute myelocytic leukemia, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  79. Czajkowski, N. P., Rosenblatt, M., Wolfe, P. L., et al., 1967, A new method of active immunization to autologous human tumor tissue, Lancet 2:905.PubMedGoogle Scholar
  80. Davies, D. A. L., and O’Neal, G. J., 1976, Specific cancer therapy by drugs attached to tumor-specific antibodies, Ann. N. Y. Acad. Sci. 277:670.Google Scholar
  81. De Carvalho, S., 1963, Preliminary experimentation with specific immunotherapy of neoplastic disease in man. I. Immediate effects of hyperimmune equine gammaglobulin, Cancer 16:306.Google Scholar
  82. Deckers, P. J., and Pilch, Y. H., 1971a, RNA-mediated transfer of tumor immunity: A new model for the immunotherapy of cancer, Cancer 28:1219.PubMedGoogle Scholar
  83. Deckers, P. J., and Pilch, Y. H., 1971b, Transfer of immunity to tumor isografts by the systemic administration of xenogeneis immune RNA, Nature (London) 231:181.Google Scholar
  84. Deckers, P. J., and Pilch, Y. H., 1972, Mediation of immunity to tumor-specific transplantation antigens by RNA inhibition of isograft growth in rats, Cancer Res. 32:839.PubMedGoogle Scholar
  85. DelGuercio, P., 1972, Adjuvant effects and antibody production against a haptenic determinant: Alternative collaboration between T and B, or B and B lymphocytes, Nature (London) 238:213.Google Scholar
  86. DeMayer, E., DeMayer, J., and Vandeputte, M., 1973, Inhibition by interferon of delayed type hypersensitivity in the mouse, Proc. Natl. Acad. Sci. (USA) 72:1753.Google Scholar
  87. Diluzio, N. R., Hoffman, E. O., Cook, J. A., et al., 1977, Glucan-induced enhancement in host resistance to experimental tumors, Natl. Cancer Inst. Monogr. (in press).Google Scholar
  88. Dimitrov, M. V., Conroy, J., Suhrland, L. G., et al., 1977, Combination therapy with C. parvum and adriamycin in patients with lung cancer, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  89. Dizon, Q. S., and Southam, C. M., 1963, Abnormal cellular response to skin abrasions in cancer patients, Cancer 16:1288.PubMedGoogle Scholar
  90. Donaldson, R. C., 1973, Chemoimmunotherapy for cancer of the head and neck, Am. J. Surg. 126:507.PubMedGoogle Scholar
  91. Douglas, S. G., Schmidt, M. E., and Dauchaday, C. C., 1976, Effect of levamisole on monocyte macrophage immunoprotein receptors and in vitro functions, Fed. Proc. 35:335.Google Scholar
  92. Drake, W. P., Cimino, E. F., Mardiney, M. R., et al., 1974, Prophylactic therapy of sponatenous leukemia in AKR mice by polyadenylic-polyuridylic acid, J. Natl. Cancer Inst. 52:941.PubMedGoogle Scholar
  93. Drake, W. P., Pendergrast, W. J., Kramer, R. E., et al., 1975, Enhancement of spontaneous C3H/HeJ mammary tumorigenesis by long-term polyadenylic-polyuridylic acid therapy, Cancer Res. 35:3051.PubMedGoogle Scholar
  94. Dupont, B., Ballow, M., Hansen, J. A., et al., 1974, Effect of transfer factor on mixed lymphocyte culture reactivity, Proc. Natl. Acad. Sci. (USA) 71:867.Google Scholar
  95. Eidinger, D., and Morales, A., 1976, Treatment of superficial bladder cancer in man, Ann. N.Y. Acad. Sci. 277:239.PubMedGoogle Scholar
  96. Eilber, F. R., and Morton, D. L., 1970, Impaired immunological reactivity and recurrence following cancer surgery, Cancer 25:362.PubMedGoogle Scholar
  97. Eilber, F. R., Nizze, J. A., and Morton, D. L., 1975, Sequential evaluation of general immune competence in cancer patients: Correlation with clinical course, Cancer 35:660.PubMedGoogle Scholar
  98. Eltringham, J. R., and Kaplan, H. S., 1973, Impaired delayed hypersensitivity: Delayed responses in 154 patients with untreated Hodgkin’s disease, Natl. Cancer Inst. Monogr. 36:107.PubMedGoogle Scholar
  99. Engstrom, P. F., Paul, A. R., Catalano, R. B., et al., 1977, Fluorouracil versus fluorouracil plus bacillus Calmette Guérin in colorectal adenocarcinoma, in: Immunotherapy of Cancer in Man: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  100. Everall, J. D., O’Donerty, C. J., Wand, J., et al., 1975, Treatment of primary melanoma by intralesional vaccinia before excision, Lancet 2:583.PubMedGoogle Scholar
  101. Falk, R. E., Mann, P., and Langer, B., 1973, Cell-mediated immunity to human tumors: Abrogation by serum factors and non-specific effects of oral BCG therapy, Arch. Surg. 107:261.PubMedGoogle Scholar
  102. Falk, R. E., MacGregor, A. D., Landi, S., et al., 1976, Immunostimulation with intraperitoneally administered bacillus Calmette Guérin for advanced malignant tumors of the gastrointestinal tract, Surg. Gynecol. Obstet. 152:363.Google Scholar
  103. Faraci, R. P., Barone, J., and Schour, L., 1975, BCG induced protection against malignant melanoma: Possible immunospecific effect in a murine system, Cancer 35:372.PubMedGoogle Scholar
  104. Farquhar, D., Loo, T. L., Gutterman, J. U., Hersh, E. M., et al., 1976, Inhibition of drug metabolizing enzymes in the rat after bacillus Calmette Guérin treatment, Biochem. Pharmacol. 25:1529.PubMedGoogle Scholar
  105. Fass, L., Herberman, R. B., Ziegler, J., et al., 1970, Evaluation of the effect of remission plasma on untreated patients with Burkitt’s lymphoma, J. Natl. Cancer Inst. 44:145.PubMedGoogle Scholar
  106. Fefer, A., 1971a, Adoptive chemoimmunotherapy of a Moloney lymphoma, Int. J. Cancer 8:364.PubMedGoogle Scholar
  107. Fefer, A., 1971b, Experimental approaches to immunotherapy of cancer, Recent Results Cancer Res. 36:182.Google Scholar
  108. Fidler, I. J., Budmen, M. B., and Hanna, M. G., 1977, Characterization of in vitro reactivity of BCG-treated guinea pigs to syngeneic line 10 hepatocarcinoma, Cancer Immunol. Immunother. (in press).Google Scholar
  109. Finger, H., Emmerling, P., and Bruss, E., 1970, Variable adjuvant activity of Bordetella pertussis with respect to the primary and secondary immunization of mice, Infect. Immun. 1:251.PubMedGoogle Scholar
  110. Fisher, B., Carbone, P., Economou, S. G., et al., 1975, L-Phenylalanine mustard (l-PAM) in the management of primary breast cancer: A report of early findings, N. Engl. J. Med. 292:117.PubMedGoogle Scholar
  111. Fishman, M. J., 1964, Antibody formation by normal mouse spleen Cell. cultures exposed in vitro to RNA from immune mice, Science 146:934.Google Scholar
  112. Flannery, G. R., Chalmers, P. J., Rolland, J. N., and Nairn, R. C. 1973, Immune response to a syngeneic rat tumor: Evolution of serum cytotoxicity and blockade, Br. J. Cancer 28:293.PubMedGoogle Scholar
  113. Fletcher, G. H., Jesse, R. H., Lindberg, R. D., et al., 1970, Radiation therapy in management of carcinoma of supraglottic larynx, Am. J. Roentgenol. 108:19.Google Scholar
  114. Fowles, R. E., Fajardo, I. M., Leibowitch, J. L., et al., 1973, The enhancement of macrophage bacteriostasis by products of activated lymphocytes, J. Exp. Med. 138:952.PubMedGoogle Scholar
  115. Frenster, J. H., 1976, Phytohemagglutinin activated autochtonous lymphocytes for systemic immunotherapy of human neoplasms, Ann. N. Y. Acad. Sci. 277:45.PubMedGoogle Scholar
  116. Freshman, M. M., Merigan, T. C., Remington, J. S., et al., 1966, In vitro and in vivo anti-viral action of an interferon-like substance induced by Toxoplasma gondii, Proc. Soc. Exp. Biol. Med. 123:862.PubMedGoogle Scholar
  117. Froese, G., Berczi, I., and Asehon, A. C., 1974, Neuraminidase induced enhancement of tumor growth in mice, J. Natl. Cancer Inst. 52:1905.PubMedGoogle Scholar
  118. Fudenberg, H. H., 1976, Dialyzable transfer factor in the treatment of human osteosarcoma an analytical review, Ann. N.Y. Acad. Sci. 277:545.PubMedGoogle Scholar
  119. Gallin, J. I., and Kirkpatrick, C. H., 1974, Chemotactic activity in dialyzable transfer factor, Proc. Natl. Acad. Sci. (USA) 71:498.Google Scholar
  120. Gallin, J. I., and Wolfe, S. M., 1975, Leukocyte Chemotaxis—Physiological considerations and abnormalities, Clin. Haematol. 4:567.PubMedGoogle Scholar
  121. Gee T. S., and Clarkson, B.D., 1977, Pseudomonas aeruginosa vaccine in a treatment protocol for adult patients with acute non-lymphoblastic leukemia: A preliminary report, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  122. Geffard, M., and Orbach-Arbouys, S., 1976, Enhancement of T-suppressor activity in mice by high doses of BCG, Cancer Immunol. Immunother. 1:41.Google Scholar
  123. Gercovich, F. G., Gutterman, J. U., Mavligit, G. M., and Hersh, E. M., 1975, Active-specific immunization in malignant melanoma, Med. Pediat. Oncol. 1:277.Google Scholar
  124. Gery, I., Baer, A., Stupp, Y., and Weiss, D. W., 1974, Further studies on the effects of the methanol extraction residue fraction of tubercle bacilli on lymphoid cells in macrophages, Israel J. Med. Sci. 10:984.Google Scholar
  125. Ghaffar, A., Cullen, R. T., and Woodruff, M. F. A., 1975, Further analysis of the antitumor effect in vitro of peritoneal exudate cells from mice treated with Corynebacteriumparvum,Br. J. Cancer 31:15.PubMedGoogle Scholar
  126. Ghose, S. E. T., Tai, J., Guclu, A., et al., 1976, Antibodies as carriers of radionuclides and cytotoxic drugs in the treatment and diagnosis of cancer, Ann. N. Y. Acad. Sci. 277:671.PubMedGoogle Scholar
  127. Ghose, T., Cerini, M., Carter, M., et al., 1967, Immunoradioactive agent against cancer, Br. Med. J. 1:90.PubMedGoogle Scholar
  128. Gibson, J. P., Megel, H., Camyre, K. P., et al., 1977, Effect of tylerone hydrochloride on the lymphoid and interferon responses of athymic mice, submitted.Google Scholar
  129. Glynn, J. P., Halpern, B. L., and Fefer, A., 1969, An immunochemotherapeutic system for the treatment for the transplanted Moloney virus-induced lymphoma in mice, Cancer Res. 29:515.PubMedGoogle Scholar
  130. Goldenberg, B. J., and Brandes, L. J., 1972, Immunotherapy of nasopharyngeal carcinoma with transfer factor from donors with previous infectious mononucleosis, Clin. Res. 20:947.Google Scholar
  131. Goldstein, A. L., Asanuma, Y., Battisto, J. R., et al., 1970, Influence of thymosin on cell-mediated and humoral immune responses in normal and immunologically’ deficient mice, J. Immunol. 104:359.PubMedGoogle Scholar
  132. Goldstein, A. L., Guha, A., Zatz, M. M., et al., 1972, Purification of biological properties of thymosin: A hormone of the thymus gland, Proc. Natl. Acad. Sci. (USA) 69:1800.Google Scholar
  133. Goldstein, A. L., Cohen, G. H., Rossio, J. L., et al., 1976, Use of thymosin in the treatment of primary immunodeficiency diseases and cancer, Med. Clin. N. Am. 60:591.PubMedGoogle Scholar
  134. Goldstein, G., 1974, Isolation of bovine thymin, a polypeptide hormone of the thymus, Nature (London) 247:11.Google Scholar
  135. Goldstein, G., 1975, The isolation of thymopoietin (thymin), Ann. N.Y. Acad. Sci. 249:177.PubMedGoogle Scholar
  136. Goldstein, G., and Hoffman, W. W., 1969, Endocrine function of the thymus affecting neuromuscular transmission, Clin. Exp. Immunol. 4:181.PubMedGoogle Scholar
  137. Golub, S. H., 1975, Host immune response to human tumor antigens, in: Cancer: A Comprehensive Treatise, Vol. 4 (F. Becker, ed.), pp. 259–302, Plenum Press, New York.Google Scholar
  138. Gordon, B. L., and Keenan, J. P., 1975, The treatment of systemic lupus erythematosus (SLE) with the T-cell immunostimulant drug levamisole: A case report, Ann. Allergy 35:343.PubMedGoogle Scholar
  139. Gorer, P. A., 1956, Some recent work on tumor immunity, Adv. Cancer Res. 4:149.PubMedGoogle Scholar
  140. Graham, J. B., and Graham, R. M., 1962, Autogenous vaccine in cancer patients, Surg. Gynecol. Obstet. 114:1.PubMedGoogle Scholar
  141. Grant, R. M., Cochran, A. J., and Hoyle, D., 1974, Results of administry of BCG to patients with melanoma, Lancet 2:1096.PubMedGoogle Scholar
  142. Green, A. A., Pratt, C., Webster, R. G., et al., 1976, Immunotherapy of osteosarcoma patients with virus modified tumor cells, Ann. N. Y. Acad. Sci. 277:396.PubMedGoogle Scholar
  143. Gresser, I., and Bourali-Maury, I., 1972, Inhibition by interferon preparations of a solid malignant tumor and pulmonary metastases in mice, Nature (London) 236:78.Google Scholar
  144. Gresser, I., Berman, L., Dethe, G., et al., 1968, Interferon and murine leukemia. V. Effect of interferon preparations on the evolution of Rauscher disease in mice, J. Natl. Cancer Inst. 41:505.PubMedGoogle Scholar
  145. Gresser, I., Bourali, C., Levy, J. P., et al., 1969, Increased survival in mice inoculated with tumor cells and treated with interferon preparations, Proc. Natl. Acad. Sci. 63:51.PubMedGoogle Scholar
  146. Gresser, I., Brouty-Boye, D., Thomas, M. T., et al., 1970, Interferon in Cell. division. I. Inhibition of the multiplication of mouse L-1210 leukemia cells in vitro by interferon preparations, Proc. Natl. Acad. Sci (USA) 66:1052.Google Scholar
  147. Grossberg, S. E., 1963, Interferon as a metabolic agent of host resistance, in: Conceptual Advances in Immunology and Oncology, pp. 116–136, Harper and Row, New York.Google Scholar
  148. Grossberg, S. E., 1972a, The interferons and their inducers: Molecular and therapeutic considerations, N. Engl. J. Med. 287:13.PubMedGoogle Scholar
  149. Grossberg, S. E., 1972b, The interferons and their inducers. Molecular and therapeutic considerations. N. Engl. J. Med. 287:122.PubMedGoogle Scholar
  150. Guthrie, D., and Way, S., 1975, Immunotherapy of non-clinical vaginal cancer, Lancet 2:1242.PubMedGoogle Scholar
  151. Gutterman, J. U., Rossen, R. D., Butler, W. T., et al., 1973a, Immunoglobulin on tumor Cell. and tumor-induced lymphocyte blastogenesis in human acute leukemia, N. Engl. J. Med. 288:169.PubMedGoogle Scholar
  152. Gutterman, J. U., Hersh, E. M., Mavligit, G. M., et al., 1973b, BCG stimulation of immune responsiveness in patients with malignant melanoma, Cancer 11:521.Google Scholar
  153. Gutterman, J. U., Mavligit, G. M., McBride, C. M., et al. 1973c, Active immunotherapy with BCG for recurrent malignant melanoma, Lancet 1:1208.PubMedGoogle Scholar
  154. Gutterman, J. U., Mavligit, G. M., McKredie, K. B., et al., 1973d, Autoimmunization with acute leukemia cells: Demonstration of increased lymphocyte responsiveness, Int. J. Cancer 11:521.PubMedGoogle Scholar
  155. Gutterman, J. U., Mavligit, G. M., Gottlieb, J. A., et al., 1974a, Chemoimmunotherapy of disseminated malignant melanoma with dimethyl imidazole carboxamide and bacillus Calmette Guérin, AT. Engl. J. Med. 291:592.Google Scholar
  156. Gutterman, J. U., Rodriguez, V., Mavligit, G. M., et al., 1974b, Chemoimmunotherapy of adult acute leukemia: Prolongation of remission in myeloblastic leukemia with BCG, Lancet 2:1405.PubMedGoogle Scholar
  157. Gutterman, J. U., Hersh, E. M., Mavligit, G. M., et al., 1974c, Cell-mediated and humoral immune response to acute leukemia cells and soluble leukemia antigen-relationship to immunocompetence and prognosis, Recent Results Cancer Res. 47:97.Google Scholar
  158. Gutterman, J. U., Mavligit, G. M., Burgess, M. A., et al., 1976, Immunotherapy of breast cancer, malignant melanoma, and acute leukemia with BCG: Prolongation of disease-free interval and survival, Cancer Immunol. Immunother. 1:99.Google Scholar
  159. Gutterman, J. U., Hersh, E. M., and Mavligit, G. M., 1977, BCG immunotherapy for recurrent metastatatic melanoma: Study of dose, strain, site of administration, degree of residual disease and immunocompetence, J. Natl. Cancer Inst. (in press).Google Scholar
  160. Haba, S., Hamaoka, T., and Takatsu, K., 1976, Selective suppression of T-cell activity in tumor-bearing mice and its improvement by lentinan, a potent antitumor polysaccharide, Natl. J. Cancer 18:93.Google Scholar
  161. Halpern, B. N., Biozzi, G., Stiffel, C., et al., 1959, Effect of the stimulation of the reticuloendothelial system by the inoculation of baccilus Calmette Guérin on the development of the atypical T8 lymphoma in the rat, C. R. Soc. Biol. (Paris) 153:919.Google Scholar
  162. Halpern, B. N., Prevot, A. R., Biozzi, G., et al., 1964, Stimulation of the phagocytic activity of the reticuloendothelial system provided by Corynebacterium parvum, J. Reticuloendothel. Soc. 1:77.Google Scholar
  163. Hamilton-Fairley, G., 1975, Immunotherapy in the management of leukemia, Br. J. Haematol. 31:181.Google Scholar
  164. Hamuro, J., Maeda, Y. Y., Arai, Y., et al., 1971, The significance of the higher structure of the polysaccharides lentinan and pachymaran with regard to their antitumor activity, Chem. Biol. Interact. 3:69.PubMedGoogle Scholar
  165. Han, T., 1973, Immune RNA-mediated transfer of delayed skin reactivity in patients with Hodgkin’s disease, Clin. Exp. Immunol. 14:213.PubMedGoogle Scholar
  166. Hanna, M. G., and Peters, L. C., 1975, Efficacy of intralesional BCG therapy in guinea pigs with disseminated tumor, Cancer 36:1298.PubMedGoogle Scholar
  167. Hanna, M. G., Zbar, B., and Rapp, H. J., 1972, Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. I. Tumor growth and metastasis, J. Natl. Cancer Inst. 48:1441.PubMedGoogle Scholar
  168. Hanna, M. G., Snodgrass, M. J., and Zbar, B., 1973, Histologic and ultrastructural studies of tumor regression in inbred guinea pigs after intralesional injection of Mycobacterium bovis (BCG), Natl. Cancer Inst. Monogr. 38:71.Google Scholar
  169. Hanna, M. G., Peters, L. C., Gutterman, J. U., and Hersh, E. M., 1977, An evaluation of BCG administered by scarification for immunotherapy of metastatic hepatocarcinoma in the guinea pig, J. Natl. Cancer Inst. 56:1013.Google Scholar
  170. Hattori, T., and Mori, A., 1973, Antitumor activity of anaerobic Corynebacterium isolated from the human bone marrow, Gann 64:15.PubMedGoogle Scholar
  171. Hawrylko, E., and Mackaness, G. B., 1973, Immunopotentiation with BCG. III. Modulation of the response to a tumor-specific antigen, J. Natl. Cancer Inst. 51:1677.PubMedGoogle Scholar
  172. Hellström, I., Hellström, K. E., Pierce, G. E., and Yang, G. P. S., 1968, Cellular and humoral immunity to different types of human neoplasms, Nature (London) 220:1352.Google Scholar
  173. Hellström, I., Sjögren, H. O., Warner, G. A., and Hellström, K. E., 1971, Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms, Int. J. Cancer 7:226.PubMedGoogle Scholar
  174. Hellström, K. E., and Hellström, I., 1974, Lymphocyte-mediated cytotoxicity in serum activity to tumor antigens, Adv. Immunol. 18:209.PubMedGoogle Scholar
  175. Hellström, K. E., and Möller, G., 1965, Immunological and immunogenetic aspects of tumor transplantation, Prog. Allergy 9:158.Google Scholar
  176. Henle, W., Henle, G., and Deinhardt, F., 1959, Studies on persistent infections in tissue cultures. IV. Evidence for the production of an interferon in MCN cells by myxovirus, J. Exp. Med. 110:525.PubMedGoogle Scholar
  177. Herberman, R. B., Rogentine, G. N., and Oren, M. E., 1969, Bioassay of antitumor effects of human allo antisera, Clin. Res. 17:328.Google Scholar
  178. Hersey, P., Isbister, J., Edwards, A., et al., 1976, Antibody-dependent cell-mediated cytotoxicity against melanoma cells induced by plasmaphoresis, Lancet 1:825.PubMedGoogle Scholar
  179. Hersh, E. M., and Freireich, E. J., 1968, Host defense mechanisms and their modification by cancer chemotherapy, in: Methods in Cancer Research, Vol. 4 (H. Busch, ed.), pp. 355–451, Academic Press, New York.Google Scholar
  180. Hersh, E. M., Gutterman, J. U., Mavligit, G. M., et al., 1974, Serial studies of immunocompetence of patients undergoing chemotherapy for acute leukemia, J. Clin. Invest. 54:401.PubMedGoogle Scholar
  181. Hersh, E. M., Gutterman, J. U., and Mavligit, G. M., 1975, Cancer and host defense mechanisms, in: Pathobiology Annual (H. L. Ioachim, ed.), pp. 133–168, Appleton-Century-Crofts, New York.Google Scholar
  182. Hersh, E. M., Gutterman, J. U., Mavligit, G. M., et al., 1976a, Immunocompetence, immunodeficiency, and prognosis in cancer, Ann. N. Y. Acad. Sci. 276:386.PubMedGoogle Scholar
  183. Hersh, E. M., Gutterman, J. U., Mavligit, G. M., McBride, C. M., and Burgess, M. A., 1976b, Immunostimulation with different BCG preparations during immunochemotherapy of melanoma, Am. Soc. Clin. Oncol. 17:246.Google Scholar
  184. Hewlett, J. S., Balcerzak, S., and Gutterman, J. U., 1977, Remission induction in adult acute leukemia by a ten-day continuous infusion of ara-C plus Oncovin and prednisone: Maintenance with and without BCG, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  185. Heyn, R. M., Joo, P., Karon, M., et al., 1975, BCG in the treatment of acute lymphatic leukemia, Blood 46:431.PubMedGoogle Scholar
  186. Hibbs, J. B., 1974, Heterocytolysis by macrophages activated by bacillus Calmette Guérin lysozome exocytosis into tumor cells, Science 184:468.PubMedGoogle Scholar
  187. Hibbs, J. B., Lambert, L. H., and Remington, J. S., 1972, Possible role of macrophage-mediated non-specific cytotoxicity in tumor resistance, Nature (London) 235:48.Google Scholar
  188. Hill, G. J., and Littlejohn, K., 1971, B16 melanoma in C57 black 6J mice: Kinetics and effects of heterologous serum, J. Surg. Oncol. 3:1.PubMedGoogle Scholar
  189. Hilleman, N. R., 1970, Double-stranded RNAs in the prevention of viral infections, Arch. Intern. Med. 126:109.PubMedGoogle Scholar
  190. Hitzig, W. H., and Grob, P. J., 1974, Therapeutic uses of transfer factor, Prog. Clin. Immunol. 2:69.PubMedGoogle Scholar
  191. Ho, M., 1964, Interferon-like viral inhibitor in rabbit after intravenous administration of endotoxin, Science 146:1472.PubMedGoogle Scholar
  192. Hoebeke, J., and Franchi, G., 1973, Influence of tetramazole and its optical isomers on the mononuclear phagocytic system: Effect on carbon clearance in mice, J. Reticuloendothel. Soc. 14:317.PubMedGoogle Scholar
  193. Hoerni, B., Chauvergne, J., Hoerni-Simon, G., et al., 1976, BCG in the immunotherapy of Hodgkin’s disease and non-Hodgkin’s lymphoma, Cancer Immunol. Immunother. 1:109.Google Scholar
  194. Holland, J. F., and Bekesi, J. G., 1976, Immunotherapy of human leukemia with neuraminidase modified cells, Med. Clin. N. Am. 60:539.PubMedGoogle Scholar
  195. Hollinshead, A. C., 1975, Analysis of soluble melanoma Cell. membrane antigens in metastatic cells of various organs and further studies of antigens present in primary melanoma, Cancer 36:1282.PubMedGoogle Scholar
  196. Hollinshead, A. C., Stewart, T. H. M., and Herberman, R. B., 1974, Delayed hypersensitivity reactions to soluble membrane extracts of human malignant lung cells, J. Natl. Cancer Inst. 52:327.PubMedGoogle Scholar
  197. Holterman, O. A., Papermaster, B. W., Rosner, D., Milgrom, H., and Klein, E., 1975, Regression of cutaneous neoplasma following delayed type hypersensitivity challenge reactions to microbial antigens or lymphokines, J. Med. 6:157.Google Scholar
  198. Hooper, J. A., McDaniel, M. C., Thurman, G. B., et al., 1975, Purification of properties of bovine thymosin, Ann. N. Y. Acad. Sci. 249:125.PubMedGoogle Scholar
  199. Hopper, D. G., Pimm, M. V., and Baldwin, R. W., 1975, Levamisole treatment of local and metastatic growth of transplanted rat tumors, Br. J. Cancer 32:345.PubMedGoogle Scholar
  200. Horn, L., and Horn, H. L., 1971, An immunological approach to therapy of cancer, Lancet 2:466.PubMedGoogle Scholar
  201. Hortobagyi, G. N., 1977, Chemoimmunotherapy of advanced breast cancer with BCG and MER, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  202. Hueper, W. C., and Russell, M., 1932, Some immunological aspects of leukemia, Arch. Intern. Med. 49:113.Google Scholar
  203. Humphrey, J. L., Jewell, W. R., Murray, D. R., et al., 1971, Immunotherapy for the patient with cancer, Ann. Surg. 173:47.PubMedGoogle Scholar
  204. Hunter-Craig, I., Newton, K. A., Westbury, G., et al., 1970, Use of vaccinia virus in the treatment of malignant melanoma, Br. Med. J. 2:512.PubMedGoogle Scholar
  205. Hynes, R. O., 1973, Alteration of cell-surface proteins by viral transformation and by proteolysis, Proc. Natl. Acad. Sci. (USA) 70:3170.Google Scholar
  206. Ikonopisov, R. L., 1975, The use of BCG in the combined treatment of malignant melanoma, in: International Symposium on Immunological Reactions to Melanoma, Antigens, pp. 206–214, Behring-werke, Hanover.Google Scholar
  207. Ikonopisov, R. L., Lewis, M. G., Hunter-Craig, I. D., et al., 1970, Autoimmunization with irradiated tumor cells in human malignant melanoma, Br. Med. J. 2:752.PubMedGoogle Scholar
  208. Irvin, G. L., and Eustace, J. C., 1970, The enhancement and rejection of tumor allografts by immune lymph node cells, Transplantation 5:55.Google Scholar
  209. Isbister, W. H., Noonan, F. P., Halliday, W. J., et al., 1975, Human thoracic duct cannulation: Manipulation of tumor-specific blocking factors in a patient with malignant melanoma, Cancer 35:1465.PubMedGoogle Scholar
  210. Israel, L., 1974, Clinical results with corynebacteria, in: Recent Results in Cancer Research: Investigations and Stimulation of Immunity in Cancer Patients (G. Mathé and R. Weiner, eds.), p. 486, Springer-Verlag, New York.Google Scholar
  211. Israel, L., Edelstein, R., DePierre, A., et al., 1975, Brief communication: Daily intravenous infusion of Corynebacterium parvum in twenty patients with disseminated cancer. A preliminary report of clinical and biological findings, J. Natl. Cancer Inst. 55:29.PubMedGoogle Scholar
  212. Jones, S. E., 1977, Chemoimmunotherapy of non-Hodgkin’s lymphoma, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  213. Jose, D. G., and Seshadri, R., 1974, Circulating immune complexes in human neuroblastoma direct assay and role in blocking specific cellular immunity, Int. J. Cancer 13:824.PubMedGoogle Scholar
  214. Jurin, M., and Suit, H. D., 1973, Transfer of resistance to tumor with lymphoid cells from immunized allogeneic donors, Texas Rep. Biol. Med. 31:29.Google Scholar
  215. Kaliss, N., 1962, The elements of immunological enhancement: Consideration of mechanisms, Ann. N.Y. Acad. Sci. 101:64.Google Scholar
  216. Kaplan, A. M., and Morahan, P. S., 1976, Macrophage-mediated tumor Cell. cytolysis, Ann. N.Y. Acad. Sci. 276:134.PubMedGoogle Scholar
  217. Kay, H., 1977, Five year follow-up of the Medical Research Council’s Concord Trial of ALL immunotherapy, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  218. Kenady, D. E., Potvin, C., Simon, R. M., et al., 1977, Thymosin modulation of T-cell levels in vitro in cancer patients, Cancer (in press).Google Scholar
  219. Khan, A., Hill, J. M., MacLellan, A., et al., 1975, Improvement in delayed hypersensitivity in Hodgkin’s disease with transfer factor, Cancer 36:86.PubMedGoogle Scholar
  220. Kimura, I., Ohnoshi, T., and Yasuhara, S., 1976, Immunotherapy in human lung cancer using a streptococcal agent OK432, Cancer 37:2201.PubMedGoogle Scholar
  221. Kint, A., and Verlinden, L., 1974, Levamisole for recurrent herpes labialis, N Engl. J. Med. 291:308.PubMedGoogle Scholar
  222. Kirkpatrick, C. H., 1975, Properties and activities of transfer factor, J. Allergy Clin. Immunol. 55:411.PubMedGoogle Scholar
  223. Kirkpatrick, C. H., and Gallin, J. I., 1975, Suppression of cellular immune responses following transfer factor: Report of a case, Cell. Immunol. 15:470.PubMedGoogle Scholar
  224. Kirkpatrick, C. H., Wilson, W. E. C., and Talmadge, D. W., 1964, Immunologic studies in human organ transplantation. I. Observation and characterization of suppressed cutaneous reactivity in uremia, J. Exp. Med. 119:727.PubMedGoogle Scholar
  225. Kirkpatrick, C. H., Rich, R. R., and Smith, P. K., 1972, Effect of transfer factor on lymphocyte function in anergic patients, J. Clin. Invest. 51:2948.PubMedGoogle Scholar
  226. Klein, E., and Holterman, O. A., 1972, Immunotherapeutic approaches to the management of neoplasms, Natl. Cancer Inst. Monogr. 35:279.Google Scholar
  227. Klein, E., Holterman, O. A., Helm, F., et al., 1975, Immunological approaches to the management of primary and secondary tumors involving the skin and soft tissues: Review of a ten year program, Transplant. Proc. 7:297.PubMedGoogle Scholar
  228. Klein, E., Holterman, O., Milgrom, H., et al., 1976, Immunotherapy for accessible tumors utilizing delayed hypersensitivity reactions and separated components of the immune system, Med. Clin. N Am. 60:389.PubMedGoogle Scholar
  229. Klein, J. J., Goldstein, A. L., and White, A., 1965, Enhancement of in vivo incorporation of labelled precursors in DNA and total protein of mouse lymph nodes after administration of thymic extracts, Proc. Natl. Acad. Sci. (USA) 53:812.Google Scholar
  230. Kollmorgen, G. M., Killion, J. J., and Sansing, W. A., 1974, Combination chemotherapy and immunotherapy of transplantable murine leukemia, in: The Cell. Cycle in Malignancy and Immunity (J. C. Hampton, ed.), NTIS, Springfield, Mass.Google Scholar
  231. Koltai, M., and Mecs, E., 1973, Inhibition of the acute inflammatory response by interferon inducers, Nature (London) 242:525.Google Scholar
  232. Krementz, E. T., and Samuels, M. S., 1967, Tumor cross-transplantation and cross-transfusion in the treatment of advanced malignant disease, Bull. Tulane Univ. Med. School 26:263.Google Scholar
  233. Kronman, B. S., Wepsic, H. T., Churchill, W. H., et al., 1970, Immunotherapy of cancer: An experimental model in syngeneic guinea pigs, Science 168:258.Google Scholar
  234. Lackovic, V., Borecky, L., Sikl, D., et al., 1970, Stimulation of interform production by mannans, Proc. Soc. Expl. Biol. Med. 134:874.Google Scholar
  235. LaGrange, P. H., and Mackaness, G. B., 1977, Effect of bacterial lypopolysaccharide on the induction and expression of cell-mediated immunity. II. Stimulation of the efferent arc, submitted.Google Scholar
  236. Lamensans, A., Chedid, L., Lederer, E., et al., 1975, Enhancement of immunity against murine syngeneic tumors by a fraction extracted from a non-pathogenic Mycobacterium,Proc. Natl. Acad. Sci. (USA) 72:3656.Google Scholar
  237. Laucius, J. F., Bodurtha, A. J., Mastrangelo, M. J., et al., 1974, Bacillus Clamette guérin in the treatment of neoplastic disease, J. Reticuloendothel. Soc. 16:347.PubMedGoogle Scholar
  238. Law, K. K., Dudrick, S. J., and Abdou, N. I., 1973, Immunocompetence of patients with protein calorie malnutrition, Ann. Intern. Med. 79:545.PubMedGoogle Scholar
  239. Lawrence, H. S., 1974, Transfer factor in cellular immunity, The Harvey Lectures Series, pp. 239–350, Academic Press, New York.Google Scholar
  240. Lawrence, H. S., 1976, Transfer factor, in: Advances in Immunology (F. J. Dickson and H. G. Kunkle, eds.), pp. 195–266, Academic Press, New York.Google Scholar
  241. Lawrence, H. S., 1949, The cellular transfer of cutaneous hypersensitivity to tuberculin in man, Proc. Soc. Exptl. Biol. 71:516.Google Scholar
  242. Lawrence, H. S., and Pappenheimer, A. M., Jr., 1956, Transfer of delayed hypersensitivity to diphtheria toxin in man, J. Exp. Med. 104:321.PubMedGoogle Scholar
  243. Lazlo, J., Buckley, C. E., and Amos, D. B., 1968, Infusion of isologous immune plasma in chronic lymphocytic leukemia, Blood 31:104.Google Scholar
  244. Lee, A. K. Y., Rowley, M., and Mackay, I. R., 1970, Antibody-producing capacity in human cancer, Br. J. Cancer 24:454.PubMedGoogle Scholar
  245. LeMonde, P., 1973, Protective effect of BCG and other bacteria against neoplasia in mice and hamsters, Natl. Cancer Inst. Monogr. 39:21.PubMedGoogle Scholar
  246. Leventhal, B. G., LePourheit, A., Halterman, R. H., et al., Immunotherapy in previously treated acute lymphatic leukemia, Natl. Cancer. Inst. Monogr. 39:177.Google Scholar
  247. Levey, R. H., Trainin, N., and Law, L. W., 1963, Evidence for function of thymic tissue in diffusion chambers implanted into neonatally thymectomized mice: Preliminary report, J. Natl. Cancer Inst. 31:199.PubMedGoogle Scholar
  248. Levin, A. S., Spitler, L. E., Stites, D. P., et al., 1970, Wiskott-Aldrich syndrome: A genetically determined cellular immunological deficiency: Clinical and laboratory responses to therapy with transfer factor, Proc. Natl. Acad. Sci. (USA) 67:821.Google Scholar
  249. Levine, S., Gibson, J. P., and Megel, H., 1974, Selective depletion of thymus-dependent areas in lymphoid tissue by tylerone, Proc. Soc. Expl. Biol. Med. 146:245.Google Scholar
  250. Levy, H. B., Law, L. W., and Rabson, A. S., 1969, Inhibition of tumor growth by polyinosinic-polycytidylic acid, Proc. Natl. Acad. Sci. (USA) 62:357.Google Scholar
  251. Likhite, V. V., and Halpern, B. N., 1973, The delayed rejection of tumors formed from the administration of tumor cells mixed with killed Corynebacterium parvum,Int. J. Cancer 12:699.PubMedGoogle Scholar
  252. Lindahl-Magnusson, P., and Gresser, I., 1972, Interferon inhibits DNA synthesis induced in mouse lymphocyte suspensions by phytohemagglutinin or by allogeneic cells, Nature (London) 237:120.Google Scholar
  253. Lindenmann, J., 1974, Viruses as immunological adjuvants in cancer, Biochim. Biophys. Acta 355:79.Google Scholar
  254. Lindstromm, B. A., 1927, An experimental study of myelotoxic sera: Therapeutic attempts in myeloid leukemia, Acta Med. Scand. Suppl. 22:1.Google Scholar
  255. Litwin, M. S., Krementz, E. T., Mansell, P. W., et al., 1975, Topical chemotherapy of lentigo muligna with 5-fluorouracil, Cancer 35:721.PubMedGoogle Scholar
  256. LoBuglio, A. F., Neidhart, J. A., Hilberg, R. W., et al., 1973, The effect of transfer factor therapy on tumor immunity in alveolar soft part sarcoma, Cell. Immunol. 7:159.PubMedGoogle Scholar
  257. Londner, M. V., Morini, J. C., Font, M. T., et al., 1968, RNA-induced immunity against the rat sarcoma, Experientia 24:596.Google Scholar
  258. Mackaness, G. B., Auclair, D. J., and LaGrange, P. H., 1973, Immunopotentiation with BCG. I. Immune response to different strains and preparations, J. Natl. Cancer Inst. 51:1655.PubMedGoogle Scholar
  259. Maddison, S. E., Hicklin, M. D., Conway, B. P., et al., 1972, Transfer factor: Delayed hypersensitivity to schistosoma mansoni and tuberculin in Macaca mulatta, Science 178:757.PubMedGoogle Scholar
  260. Maeda, Y. Y., and Chihara, G., 1973, The effects of neonatal thymectomy on the antitumor activity of lentinan carboxymethyl pachymaran and zymosan, and their effects on various immune responses, Int. J. Cancer 11:153.PubMedGoogle Scholar
  261. Mansell, P. W. A., Ichinose, H., and Reed, R. J., 1975, Macrophage-mediated destruction of human malignant cells in vivo, J. Natl. Cancer Inst. 54:571.PubMedGoogle Scholar
  262. Mantovani, A., and Spreafico, F., 1975, Allogeneic tumor enhancement by levamisole: A new immunostimulatory compound, Eur. J. Cancer 11:537.PubMedGoogle Scholar
  263. Marcove, R. C., Southam, C. M., Levin, A., et al., 1971, A clinical trial of autogenous vaccine in osteogenic sarcoma in patients under the age of twenty-five, Surg. Forum 22:434.PubMedGoogle Scholar
  264. Marshall, W. H., 1972, Transfer of immune responsiveness, Med. Clin. N. Am. 56:465.PubMedGoogle Scholar
  265. Martin, D. S., Hayworth, P., and Fugmann, R. A., 1964, Combination therapy with cyclophosphamide and zymosan on a spontaneous mammary cancer in mice, Cancer Res. 24:652.PubMedGoogle Scholar
  266. Mastrangelo, M. J., Bellet, R. E., and Berkelhammer, J., 1975, Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases, Cancer 36:1305.PubMedGoogle Scholar
  267. Mastrangelo, M. J., Sulit, H. L., Prehn, L. M., et al., 1976, Intralesional BCG in the treatment of metastatic malignant melanoma, Cancer 37:684.PubMedGoogle Scholar
  268. Mastrangelo, M. J., Bellet, R. E., and Berd, D., 1977, A randomized prospective trial comparing MECCNU plus vincristine to MECCNU plus vincristine plus BCG plus allogeneic tumor cells in patients with metastatic malignant melanoma, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  269. Mathé, G., Amiel, J. L., Schwarzenberg, L., Schneider, M., et al., 1969a, Active immunotherapy for acute lymphoblastic leukemia, Lancet 1:697.PubMedGoogle Scholar
  270. Mathé, G., Gouillart, P., and Lapeyraque, F., 1969a, Active immunotherapy of L-1210 leukemia applied after the graft of tumor cells, Br. J. Cancer 23:814.PubMedGoogle Scholar
  271. Mathé, G., Kamel, M., and Dezfulian, M., 1973a, An experimental screening for systemic adjuvants of immunity applicable in cancer immunology, Cancer Res. 33:1987.PubMedGoogle Scholar
  272. Mathé, G., Weiner, R., Pouillart, P., et al., 1973b, BCG in cancer immunotherapy: Experimental and clinical trials of its use in treatment of leukemia minimal and/or residual disease, Natl. Cancer Inst. Monogr. 39:165.PubMedGoogle Scholar
  273. Mavligit, G. M., Gutterman, J. U., Burgess, M. A., et al., 1976, Prolongation of post-operative disease-free interval and survival in human colorectal cancer by BCG or BCG plus 5-fluorouracil, Lancet 1:871.PubMedGoogle Scholar
  274. Mayer, G. D., and Krueger, R. F., 1970, Tylerone hydrochloride and orally active antiviral agent, Science 169:1213.PubMedGoogle Scholar
  275. McBride, W. H., Weir, D. M., Kay, A. B., et al., 1975, Activation of the classical and alternate pathways of complement by C. parvum, Clin. Expl. Immunol. 19:143.Google Scholar
  276. McDaniel, M. C., Laudico, R., and Papermaster, B.W., 1976, Association of macrophage activation factor from a human cultured lymphoid Cell. line with albumin and alpha-2-macroglobulin, Clin. Immunol. Immunopathol. 5:91.PubMedGoogle Scholar
  277. McIntyre, O. R., Rai, K., Glidewell, O., et al., 1977, Poly-I-poly-C as an adjunct to remission maintenance therapy in acute myelogenous leukemia, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  278. McKneally, M. F., Maver, C., and Kausel, H. W., 1976, Regional immunotherapy of lung cancer with intrapleural BCG, Lancet 1:377.PubMedGoogle Scholar
  279. Medical Research Council, 1971, Treatment of acute lymphoblastic leukemia, Br. Med. J. 4:189.Google Scholar
  280. Meyer, T. J., E., and Azuma, I., 1975, Biologically active components from mycobacterial cell walls. V. Granuloma formation in mouse lungs and guinea pig skin, Cell. Immunol. 16:11.PubMedGoogle Scholar
  281. Milas, L., Hunter, N., and Basic, I., 1974a, Complete regressions of an established murine fibrosarcoma induced by systemic application of Corynebacterium granulosum,Cancer Res. 34:2470.PubMedGoogle Scholar
  282. Milas, L., Gutterman, J. U., Basic, I., Hersh, E. M., et al., 1974b, Immunoprophylaxis and immunotherapy for a murine fibrosarcoma with C. granulosum and C. parvum,Int. J. Cancer 14:493.PubMedGoogle Scholar
  283. Milas, L., Hunter, N., and Withers, H. R., 1975, Combination of local irradiation with systemic application of anaerobic corynebacteria in therapy of a murine fibrosarcoma, Cancer Res. 35:1274.Google Scholar
  284. Miller, J. F. A. P., and Osoba, D., 1967, Current concepts of the immunological function of the thymus, Physiol. Rev. 47:437.PubMedGoogle Scholar
  285. Miller, T. E., Mackaness, G. B., and LaGrange, P. H., 1973, Immunopotentiation with BCG. II. Modulation of the response to sheep red blood cells, J. Natl. Cancer Inst. 51:1669.PubMedGoogle Scholar
  286. Minden, P., McClatchy, J. K., Wainberg, M., and Weiss, D. W., 1974, Shared antigens between Mycobacterium bovis (BCG) and neoplastic cells, J. Natl. Cancer Inst. 53:1325.PubMedGoogle Scholar
  287. Modolell, M., Luckenbach, G. A., Parant, M., et al., The adjuvant activity of a mycobacterial water soluble adjuvant (WSA) in vitro,J. Immunol. 113:395.Google Scholar
  288. Moertel, C. G., Ritts, R. E., Schutt, A. J., et al., 1975, A phase I study of methanol extraction residue of BCG (MER-BCG), Proc. Am. Assoc. Cancer Res. 16:143.Google Scholar
  289. Moertel, C. G., O’Connell, M. J., Ritts, R. E., et al., 1977, A controlled evaluation of combination immunotherapy (MER-BCG) and chemotherapy for advanced colorectal cancer, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  290. Mohr, J. A., Killebrew, L., Muchmore, H. G., et al., 1969, Transfer of delayed hypersensitivity: The role of blood transfusions in humans, J. Am. Med. Assoc. 207:517.Google Scholar
  291. Moller, G., and Moller, E., 1975, Considerations of current concepts in cancer research, J. Natl. Cancer Inst. 55:755.PubMedGoogle Scholar
  292. Moolten, F., Zajedel, S., and Cooperband, S., 1976, Immunotherapy of experimental animal tumors with antitumor antibodies conjugated to diphtheria toxin or ricin, Ann. N. Y. Acad. Sci. 277:690.PubMedGoogle Scholar
  293. Monard, D., Soloman, F., Rentsch, M., and Gysin, R., 1973, Glia-induced morphological differentiation in neuroblastoma cells, Proc. Natl. Acad. Sci. (USA) 70:1894.Google Scholar
  294. Moore, G. E., and Gerner, R. E., 1970, Cancer immunity: Hypothesis and clinical trial of lymphocytotherapy for malignant disease, Ann. Surg. 172:733.PubMedGoogle Scholar
  295. Morse, P. A., Deraps, G. D., Smith, G. V., et al., 1973, Transfer factor therapy of human cancer, Clin. Res. 21:71.Google Scholar
  296. Morton, D. L., 1977, Clinical trial comparing no further therapy to BCG or BCG plus allogeneic cells in stage II melanoma, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  297. Morton, D. L., Eilber, F. R., Malmgren, R. A., et al., 1970, Immunological factors which influence response to immunotherapy in malignant melanoma, Surgery 68:158.PubMedGoogle Scholar
  298. Morton, D. L., Eilber, F. R., and Malmgren, R. A., 1971a, Immune factors in human cancer: Malignant melanomas, skeletal and soft tissue sarcomas, Prog. Exp. Tumor Res. 14:25.PubMedGoogle Scholar
  299. Morton, D. L., Holmes, E. C., Eilber, F. R., et al., 1971b, Immunological aspects of neoplasia: A rational basis for immunotherapy, Ann. Intern. Med. 74:587.Google Scholar
  300. Morton, D. L., Eilber, F. R., Holmes, E. C., et al., 1974, BCG immunotherapy of malignant melanoma: Summary of seven years experience, Ann. Surg. 180:635.PubMedGoogle Scholar
  301. Mosedale, B., and Smith, M. A., 1975, Corynebacterium parvum and anesthetics, Lancet 1:168.PubMedGoogle Scholar
  302. Muftuoglou, A. U., and Balkur, S., 1967, Passive transfer of tuberculin sentitivity to patients with Hodgkin’s disease, N. Engl. J. Med. 277:126.Google Scholar
  303. Munson, A. E., Regelson, W., and Wooles, W., 1970, Tissue localization studies in evaluating the functional role of the reticuloendothelial system, J. Reticuloendothel Soc. 7:366.PubMedGoogle Scholar
  304. Munson, A. E., Munson, J. A., Regelson, W., et al., 1972, Effect of tylerone hydrochloride and cogenes on reticuloendothelial system: Tumors, and the immune response, Cancer Res. 32:1397.PubMedGoogle Scholar
  305. Murray, G., 1958, Experiments in immunity in cancer, Can. Med. Assoc. J. 79:249.PubMedGoogle Scholar
  306. Nadler, S. H., and Moore, G. E., 1969, Immunotherapy of malignant disease, Arch. Surg. 99:376.PubMedGoogle Scholar
  307. Nauts, H. C., 1975, Osteogenic Sarcoma: End Results Following Immunotherapy with Bacterial Vaccines, 165 Cases, or Following Bacterial Infections Inflammation or Fever, 41 cases, Monograph No. 15, Cancer Research Institute, New York.Google Scholar
  308. Newlands, E. S., Oon, C. J., Roberts, J. T., et al., 1976, Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma, Br. J. Cancer 34:174.PubMedGoogle Scholar
  309. Ngu, V. A., 1967, Clinical evidence of host defenses in Burkitt’s tumor, in: Treatment of Burkitt’s Tumor (J. H. Burchenal and D. P. Burkitt, eds.), pp. 204–208, Springer-Verlag, New York.Google Scholar
  310. Novelli, D., 1976, A biochemist’s view of the mediators of cellular immunity with special reference to application, in: Transfer Factor: Basic Properties and Clinical Application (M. S. Ascher, A. Gottlieb, and C. H. Kirkpatrick, eds.), pp. 723–739, Academic Press, New York.Google Scholar
  311. Occhino, J. C., Glasgow, A. H., and Cooperband, S. R., 1973, Isolation of an immunosuppressive peptide fraction from human plasma, J. Immunol. 110:685.PubMedGoogle Scholar
  312. Oettgen, H. F., Old, L. J., Farrow, J. H., et al., 1974, Effect of dialyzable transfer factor in patients with breast cancer, Proc. Natl. Acad. Sci. (USA) 71:2319.Google Scholar
  313. Old, L. J., Clark, D. A., and Benacerraf, B., 1959, Effective bacillus Calmette Guérin infection on transplanted tumors in the mouse, Nature 184:291.PubMedGoogle Scholar
  314. Oyama, K., Takagaki, Y., Niki, R., et al., 1975, Studies on the interrelation between clinical effects and immune response of a streptococcal antitumor agent OK432. I. Immunological findings in animals sensitized with OK432, Jpn. J. Clin. Cancer 21:253.Google Scholar
  315. Pabst, H. F., and Crawford, J. A., 1974, Enhancement of in vitro cellular immune response by L-tetramizole, Pediat. Res. 8:416.Google Scholar
  316. Papermaster, B. W., Holterman, O. A., McDaniel, M. C., et al., 1976a, Effect of supernatants from long-term lymphoid Cell. lines on metastatic cutaneous tumors following local injection, Ann. N. Y. Acad. Sci. 276:584.PubMedGoogle Scholar
  317. Papermaster, B.W., Holterman, O. A., and Klein, E., 1976b, Lymphokine properties of a lymphoid culture Cell. supernatant fraction active in promoting tumor regression, Clin. Immunol. Immunopathol. 5:48.PubMedGoogle Scholar
  318. Papermaster, B. W., Holterman, O. A., Klein, E., et al., 1976c, Preliminary observations on tumor regressions induced by local administration of a lymphoid Cell. culture supernatant fraction in patients with cutaneous metastatic lesions, Clin. Immunol. Immunopathol. 5:31.PubMedGoogle Scholar
  319. Paque, R. E., and Dray, S., 1974, Transfer of delayed hypersensitivity to nonsensitive human leukocytes with rhesus monkey lymphoid RNA extracts, Transplant. Proc. 6:203.PubMedGoogle Scholar
  320. Paque, R. E., Ali, M., and Dray, S., 1975, RNA extracts of lymphoid cells sensitized to DNP-oligolysines convert non-responder lymphoid cells to responder cells which release migration inhibitory factor, Cell. Immunol. 16:261.PubMedGoogle Scholar
  321. Parr, I., 1972, Response of syngeneic murine lymphomata to immunotherapy in relation to the antigenicity of the tumor, Br. J. Cancer 26:174.PubMedGoogle Scholar
  322. Paslin, D., Dimitrov, N. V., and Heaton, C., 1974, Regression of transplantable hamster melanoma by intralesional injections of C. granulosum, J. Natl. Cancer Inst. 52:571.PubMedGoogle Scholar
  323. Pearson, J. W., Pearson, G. R., Gibson, W. T., et al., 1972, Combination chemoimmuno stimulation therapy against murine leukemia, Cancer Res. 32:904.PubMedGoogle Scholar
  324. Pearson, J. W., Chirigos, M. A., and Chaparas, S. V., 1974, Combined drug and immunostimulation therapy against a syngeneic murine leukemia, J. Natl. Cancer Inst. 52:463.PubMedGoogle Scholar
  325. Pendergrast, W. J., Drake, W. P., and Mardiney, M. R., 1975, The dependence of successful immunotherapy on adequate tumor burden as shown by the treatment of AKR leukemia with poly-A, poly-U, J. Natl. Cancer Inst. 55:1223.PubMedGoogle Scholar
  326. Penn, I., and Starzl, T. E., 1972, Malignant tumors de novo in immunosuppressed organ transplant recipients, Transplantation 14:407.PubMedGoogle Scholar
  327. Penny, R., Castaldi, P. A., and Whitsed, H. M., 1971, Inflammation and hemostasis in paraproteinemias, Brit. J. Haematol. 20:35.Google Scholar
  328. Perk, K., Chirigos, M. A., Fuhrman, F., et al., 1975, Some aspects of host response to levamisole after chemotherapy in a murine leukemia, J. Natl. Cancer Inst. 54:253.PubMedGoogle Scholar
  329. Peto, R., 1977, Immunotherapy of acute myeloid leukemia, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  330. Phanuphak, P., Moorhead, J. W., and Claman, H. N., 1972, Immunological activities of pertussis treated lymphocytes, Int. Arch. Allergy Appl. Immunol. 43:305.PubMedGoogle Scholar
  331. Piessens, W. F., Lachapelle, F. L., Legros, N., et al., 1970, Facilitation of rat mammary tumour growth by BCG, Nature (London) 228:1210.Google Scholar
  332. Pilch, Y. H., and Ramming, K. P., 1970, Transfer of tumor immunity with ribonucleic acid, Cancer 26:630.PubMedGoogle Scholar
  333. Pilch, Y. H., Ramming, K. P., and Deckers, P. J.: Transfer of immunity to transplantation and tumor-specific antigens by RNA from lymphoid organs of xenogeneic, allogeneic, and syngeneic animals, Transplant. Proc. 3:566.Google Scholar
  334. Pilch, Y. H., Veltman, L. L., and Kern, D. H., 1974, Immune cytolysis of human tumor cells mediated by xenogeneic immune RNA, Arch. Surg. 109:30.PubMedGoogle Scholar
  335. Pilch, Y. H., Fritze, D., and Kern, D. H., 1976a, Immune RNA in the immunotherapy of cancer, Med. Clin. N Am. 60:567.PubMedGoogle Scholar
  336. Pilch, Y. H., Fritze, D., Dekernion, J. B., et al., 1976b, Immunotherapy of cancer with immune RNA in animal models and cancer patients, Ann. N.Y. Acad. Sci. 277:592.PubMedGoogle Scholar
  337. Pimm, M. V., and Baldwin, R. W., 1975a, BCG therapy of pleural and peritoneal growth of transplanted rat tumors, Int. J. Cancer 15:260.PubMedGoogle Scholar
  338. Pimm, M. B., and Baldwin, R. W., 1975b, BCG immunotherapy of rat tumors in athymic “nude” mice, Nature (London) 254:77.Google Scholar
  339. Pines, A., 1976, A five-year controlled study of BCG and radiotherapy for inoperable lung cancer, Lancet 1:380.PubMedGoogle Scholar
  340. Pinsky, C. M., Hirshaut, Y., and Oettgen, H. F., 1973, Treatment of malignant melanoma by intratumoral injection of BCG, Natl. Cancer Inst. Monogr. 39:225.PubMedGoogle Scholar
  341. Pinsky, C. M., Hirshout, Y., Wanebo, H., et al., 1976, Randomized trial of bacillus Calmette Guéri’n (percutaneous administration) as surgical adjuvant: Immunotherapy for patients with stage II melanoma, Ann. N.Y. Acad. Sci. 277:187.PubMedGoogle Scholar
  342. Pinsky, M., DeJager, R. L., Kaufman, R. J., et al., 1977, Corynebacterium parvum as adjuvant to combination chemotherapy in patients with advanced breast cancer: Preliminary results of a prospective randomized trial, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  343. Pollack, S., Heppner, G., Braun, R. J., et al., Specific killing of tumor cells in vitro in the presence of normal lymphoid cells and sera from hosts immune to the tumor antigens, Int. J. Cancer 9:316.Google Scholar
  344. Potter, C. W., Carr, I., Jennings, R., et al., 1974, Levamisole inactive in treatment of four animal tumors, Nature (London) 249:567.Google Scholar
  345. Powles, R., Crowther, D., Bateman, C. T. J., et al., 1973, Immunotherapy for acute myelogenous leukemia, Br. J. Cancer 28:365.PubMedGoogle Scholar
  346. Prager, M. D., Ribble, R. J., and Mehta, J. M., 1974, Aspects of the immunology of the tumor host relationship and responsiveness to modified lymphoma cells, Recent Results Cancer Res. 47:379.Google Scholar
  347. Presant, C. A., Bartolucci, A., Smalley, R., et al., 1977, Effect of C parvum (Cp) on combination chemotherapy of metastatic malignant melanoma, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  348. Purnell, D. M., Kreider, J. W., and Bartlett, G. L., 1975, Evaluation of antitumor activity of Bordetella pertussis in two murine tumor models, J. Natl. Cancer Inst. 55:123.PubMedGoogle Scholar
  349. Quick, C. A., Behrens, H. W., Darnell, M. B., et al., 1975, Treatment of papillomatosis of the larynx with transfer factor, Ann. Otolaryngol. 84:607.Google Scholar
  350. Ramming, K. P. and Pilch, Y. H., 1970a, Mediation of immunity to tumor isografts in mice by heterologous ribonucleic acid, Science 168:492.PubMedGoogle Scholar
  351. Ramming, K. P., and Pilch, Y. H., 1970b Transfer of tumor-specific immunity with RNA: Demonstration by immune cytolysis of tumor cells in vitro, J. Natl. Cancer Inst. 45:543.Google Scholar
  352. Ramming, K. P., and Pilch, Y. H., 1971, Transfer of tumor-specific immunity with RNA: Inhibition of growth of murine tumor isografts, J. Natl. Cancer Inst. 46:735.PubMedGoogle Scholar
  353. Ramot, B., Biniaminov, M., Shoham, C., et al., 1976, Effect of levamisole on E-rosette forming cells in vivo and in vitro in Hodgkin’s disease, N. Engl. J. Med. 294:809.PubMedGoogle Scholar
  354. Reed, R. C., Gutterman, J. U., Mavligit, G. M., et al., 1975, Corynebacterium parvum: Preliminary report of a phase I clinical and immunological study in cancer patients, in: Corynebacterium parvum (B. N. Halpern, ed.), pp. 349–366, Plenum Press, New York.Google Scholar
  355. Regelson, W., 1976, Clinical immunoadjuvant studies with tylorone, Ann. N.Y. Acad. Sci. (USA) 277:269.Google Scholar
  356. Reif, A. E., Robinson, C. M., and Smith, P. J., 1976, Preparation and therapeutic potential of rabbit antisera with directed specificities for mouse leukemias, Ann. N. Y. Acad. Sci. 277:647.PubMedGoogle Scholar
  357. Reisfeld, R. A., Pellegrino, M. A., and Kahan, B. D., 1971, Salt extraction of soluble HLA antigens, Science 172:1134.PubMedGoogle Scholar
  358. Reizenstein, P., Brenning, G., Engstedt, L., et al., 1977, Effective immunotherapy on survival and remission duration in acute non-lymphatic leukemia, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  359. Renoux, G., and Renoux, M., 1972, Levamisole inhibits and cures a solid malignant tumor and its pulmonary metastases in mice, Nature (London) 240:217.Google Scholar
  360. Renoux, G., and Renoux, M., 1973, Stimulation of anti-brucella vaccination in mice by tetramisole, a phenyl-imidothiazole salt, Infect. Immun. 8:544.PubMedGoogle Scholar
  361. Rhim, J. S., Huebner, R. J., and Gisin, S., 1969, Effect of statolon on acute and persistent murine leukemia and sarcoma virus infections, Proc. Soc. Exp. Biol. Med. 130:181.PubMedGoogle Scholar
  362. Ribi, E., Meyer, T. J., Azuma, I., et al., 1975a, Biologically active components from mycobacterial cell walls. Protection of mice against aerosol infection with virulent Mycobacterium tuberculosis, Cell. Immunol. 16:1.PubMedGoogle Scholar
  363. Ribi, E., Granger, D. L., Milner, K. C., et al., 1975b, Tumor regression caused by endotoxins and mycobacterial fractions, J. Natl. Cancer Inst. 55:1253.PubMedGoogle Scholar
  364. Ribi, E., Milner, K., Kelly, M. T., et al., 1977, Structural requirements of microbial agents for immunotherapy of the guinea pig line-10 tumor, in: Present Status of BCG in Cancer Immunotherapy, in press.Google Scholar
  365. Richman, S. P., Mavligit, G. M., Wolk, R., et al., 1975, Epilesional scarification: Preliminary report of a new approach to local immunotherapy with BCG, J. Am. Med. Assoc. 234:1233.Google Scholar
  366. Richman, S. P., Livingston, R. B., Gutterman, J. U., et al., 1976, Chemotherapy versus chemo-immunotherapy of head and neck cancer: Report of a randomized study, Cancer Treat Rep. 60:535.PubMedGoogle Scholar
  367. Rigby, P. G., 1969, Prolongation of survival of tumor-bearing animals by transfer of immune RNA with DEAE dextran, Nature (London) 221:968.Google Scholar
  368. Roberts, S., and White, A., 1949, Biochemical characterization of lymphoid tissue proteins, J. Biol Chem. 178:151.PubMedGoogle Scholar
  369. Rojas, A. F., Mickiewicz, E., Feierstein, J. N., et al., 1976, Levamisole in advanced human breast cancer, Lancet 1:211.PubMedGoogle Scholar
  370. Schlager, S.T., Dray, S., and Paque, R. E., 1974, Atomic spectroscopic evidence for the absence of a low molecular weight antigen in RNA extracts shown to transfer delayed type hypersensitivity in vitro, Cell. Immunol. 14:104.PubMedGoogle Scholar
  371. Schmidtke, J. R., and Johnson, A. G., 1971, Regulation of the immune system by synthetic polynucleotides. I. Characteristics of adjuvant action on antibody synthesis, J. Immunol. 106:1191.PubMedGoogle Scholar
  372. Schwartz, D. B., Zbar, B., Gibson, W. T., and Chirigos, M. A., 1971, Inhibition of murine sarcoma virus oncogenesis with living BCG, Int. J. Cancer 8:320.PubMedGoogle Scholar
  373. Schwarzenberg, L., Mathé, G., Schneider, M., et al., 1966, Attempted adoptive immunotherapy of acute leukemia by leukocyte transfusions, Lancet 2:365.PubMedGoogle Scholar
  374. Scott, M. T., 1972, Biological effects of the adjuvant Corynebacterium parvum: inhibition of PHA, mixed lymphocytes, and GVH reactivity, Cell. Immunol. 5:459.PubMedGoogle Scholar
  375. Scott, M. T., 1974a, Corynebacterium parvum as a therapeutic antitumor agent in mice I. Systemic effects from intravenous injection, J. Natl. Cancer Inst. 53:855.PubMedGoogle Scholar
  376. Scott, M. T., 1974b, Corynebacterium parvum as a therapeutic antitumor agent in mice. II. Local injection, J. Natl. Cancer Inst. 53:861.PubMedGoogle Scholar
  377. Scott, M. T., 1974c, Corynebacterium parvum as an immunotherapeutic anti-cancer agent, Sem. Oncol. 1:367.Google Scholar
  378. Scott, M. T., 1974d, Depression of delayed type hypersensitivity by Corynebacterium parvum: Mandatory role of the spleen, Cell. Immunol. 13:251.PubMedGoogle Scholar
  379. Scott, M. T., 1974e, Corynebacterium parvum as an immunotherapeutic anti-cancer agent, Sem. Oncol 1:367.Google Scholar
  380. Rosato, F. E., Miller, E., Rosato, E. F., et al., 1976, Active-specific immunotherapy of human solid tumors, Ann. N.Y. Acad. Sci. 277:332.PubMedGoogle Scholar
  381. Rosenberg, E. B., Kanner, S. P., Schwartzman, R. J., et al., 1974, Systemic infection following BCG therapy, Arch. Intern. Med. 134:769.PubMedGoogle Scholar
  382. Rosenberg, S. A., and Rapp, H. J., 1976, Intralesional immunotherapy of melanoma with BCG, Med. Clin. N Am. 60:419.PubMedGoogle Scholar
  383. Ruckdeschel, J. C., Codish, S. D., Stranahan, A., et al., 1972, Post-operative empyema improved survival in lung cancer: Documentation and analysis of a natural experiment, N. Engl. J. Med. 287:1013.PubMedGoogle Scholar
  384. Sadler, T. E., and Castro, J. E., 1975, Lack of immunological and antitumor effects of orally administered, Corynebacterium parvum in mice, Br. J. Cancer 31:359.PubMedGoogle Scholar
  385. Salaman, N. R., 1974, Studies on the transfer factor of delayed hypersensitivity, Immunology 26:1069.PubMedGoogle Scholar
  386. Sampson, D., and Lui, A., 1975, The effect of levamisole on cell-mediated immunity and suppressor cell function, Cancer Res. 36:952.Google Scholar
  387. Sauter, C., Cavalli, F., and Lindenmann, J., 1977, Viral oncolysis: Its application in maintenance treatment of acute myelogenous leukemia, in: Immunotherapy of Cancer in Man: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  388. Schafer, L. A., Goldstein, A. L., Gutterman, J. U., and Hersh, E. M., 1976, In vitro and in vivo studies with thymosin in cancer patients, Ann. N. Y. Acad. Sci. 277:609.PubMedGoogle Scholar
  389. Schlager, S. I., and Dray, S., 1975, Tumor regression at an untreated site during immunotherapy of an identical distant tumor, Proc. Natl. Acad. Sci. 72:3680.PubMedGoogle Scholar
  390. Scott, M. T., and Warner, S. L.4, 1976, The accumulated effects of repeated systemic or local injections of low doses of C. parvum in mice, Cancer Res. 36:1335.PubMedGoogle Scholar
  391. Serrou, B., Reme, T., and Senelar, R., 1975, T-lymphocyte maturation and antitumor effect of a thymic extract obtained from a stimulated model, Ann. N. Y. Acad. Sci. 249:328.PubMedGoogle Scholar
  392. Siegler, H. F., Buckley, C. E., and Sheppard, L., 1976, Adoptive transfer and specific active immunization with patients with malignant melanoma, Ann. N.Y. Acad. Sci. 277:522.Google Scholar
  393. Simmons, R. L., 1977, Comparison of chemotherapy to chemotherapy plus VCN treated autologous tumor cells in stage II and III melanoma, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  394. Simmons, R. L., and Rios, A., 1971, Immunotherapy of cancer, immunospecific rejection of tumors in recipients of neuraminidase-treated tumor cells plus BCG, Science 174:591.PubMedGoogle Scholar
  395. Simmons, R. L., and Rios, A., 1975, Comparative immunotherapeutic effect of concanavalin-A and neuraminidase-treated cancer cells, Transplant. Proc. 7:247.PubMedGoogle Scholar
  396. Simmons, R. L., Rios, A., Ray, P. K., et al., 1971, Effect of neuraminidase on growth of a 3-methylcholantherene-induced fibrosarcoma in normal and immunosuppressed syngeneic mice, J. Natl. Cancer Inst. 47:1087.PubMedGoogle Scholar
  397. Simmons, R. L., Rios, A., and Trites, P., 1976, Modified tumor cells in the immunotherapy of solid mammary tumors, Med. Clin. N. Am. 60:551.PubMedGoogle Scholar
  398. Shibata, H. R., Jerry, L. M., Lewis, M. G., et al., 1976, Immunotherapy of human malignant melanoma with irradiated tumor cells, oral bacillus Calmette Guérin, and levamisole, Ann. N. Y. Acad. Sci. 277:355.PubMedGoogle Scholar
  399. Skurkovich, S. V., Makhonova, F. M., and Reznichenki, G. I., et al., 1969, Treatment of children with acute leukemia by passive cyclic immunization with autoplasma and auto-leukocytes operated during the remission period, Blood 33:186.PubMedGoogle Scholar
  400. Skurzak, H. M., Klein, E., Yoshida, T. O., et al., 1972, Synergistic or antagonistic effect of different antibody concentrations on in vitro leukocyte cytotoxicity in the Moloney sarcoma virus system, J. Exp. Med. 135:997.PubMedGoogle Scholar
  401. Smith, S. E., and Scott, M. T., 1972, Biological effects of Corynebacteriumparvum III. Amplification of resistance and impairment of active immunity to murine tumors, Br. J. Cancer 26:361.PubMedGoogle Scholar
  402. Sokal, J. E., Aungst, C. W., and Grace, J. T., 1973, Immunotherapy in well-controlled chronic myelocytic leukemia, N.Y. State J. Med. 73:1180.PubMedGoogle Scholar
  403. Sokal, J. E., Aungst, C. W., and Schneiderman, M., 1974, Delay in progression of malignant lymphoma after BCG vaccination, N. Engl. J. Med. 291:1226.PubMedGoogle Scholar
  404. Sokal, J. E., Aungst, C. W., Schneiderman, M., et al., 1976, Immunotherapy of chronic myelocytic leukemia: Effects of different vaccination schedules, Ann. N.Y. Acad. Sci. 277:367.PubMedGoogle Scholar
  405. Soloway, A. C., Rappaport, F. T., and Lawrence, H. S., 1968, Cellular studies in neoplastic disease, in: Histocompatibility Testing (E. S. Curtin et al., eds.), pp. 75–78, Munksgaard, Copenhagen.Google Scholar
  406. Sparks, F. C., 1976, Hazrds and complications of BCG immunotherapy, Med. Clin. N. Am. 60:499.PubMedGoogle Scholar
  407. Spitler, L. E., Levin, A. S., Stites, D. E., et al., 1972, The Wiskott-Aldrich syndrome: Results of transfer factor therapy, J. Clin. Invest. 51:3216.PubMedGoogle Scholar
  408. Spitler, L. E., Levin, A. S., and Fudenberg, H. H., 1973, Human lymphocyte transfer factor, Methods Cancer Res. 8:59.Google Scholar
  409. Spitler, L. E., Sagebiel, R., Wong, P., et al., 1977, A randomized double-blind trial of adjuvant therapy with levamisole in patients with malignant melanoma, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  410. Spreafico, F., Vecchi, A., Mantovani, A., et al., 1975, Characterization of the immunostimulants levamisole and tetramizole, Eur. J. Cancer 11:555.PubMedGoogle Scholar
  411. Stern, K., 1960, The reticuloendothelial system and neoplasia, in: The Reticuloendothelial System Structure and Function (J. H. Heller, ed.), pp. 233–258, Ronald Press, New York.Google Scholar
  412. Stewart, T. H. M., Hollinshead, A. C., Harris, J. E., et al., 1976, Immunochemotherapy of lung cancer, Ann. N. Y. Acad. Sci. 277:436.PubMedGoogle Scholar
  413. Stewart, W. E., Gresser, I., Tovey, M. G., et al., 1976, Identification of the Cell. multiplication inhibitory factors in interferon preparations as interferons, Nature (London) 262:300.Google Scholar
  414. Stiffel, C., Mouton, D., and Bouthillier, Y., et al., 1970, Response of RES to Mycobacterium tuberculosis BCG and to Corynebacterium parvum in mice of different strains, J. Reticuloendothel Soc. 7:280.PubMedGoogle Scholar
  415. Stjernsward, J., and Levin, A., 1971, Delayed hypersensitivity induced regression of human neoplasms, Cancer 28:628.PubMedGoogle Scholar
  416. Strander, H., 1975, in: International Workshop on Interferon in the Treatment of Cancer (M. Crim, A. S. Levine, T. C. Merrigan, and J. Vilcek, eds.), submitted.Google Scholar
  417. Strander, H., Cantell, K., Carlstrom, G., et al., 1975, Clinical and laboratory investigations in man: Systemic administration of potent interferon to man, J. Natl. Cancer Inst. 51:733.Google Scholar
  418. Sumner, W. C., and Foraker, A. G., 1960, Spontaneous regression of human melanoma: Clinical and experimental studies, Cancer 13:79.PubMedGoogle Scholar
  419. Sunshine, G., Lopez-Corrales, E., Hadden, E. M., et al., 1977, Levamisole and imidazole in vitro effects in mouse and man and their possible mediation by cyclic nucleotides, Fogarty Int. Cent. Proc. 28:31.Google Scholar
  420. Symdens, J., and Brugmans, J., 1974, Treatment of recurrent aphthous stomatitis and herpes infections with levamisole, Br. Med. J. 2:592.Google Scholar
  421. Symes, M. O., and Riddell, A. G., 1968, Immunologically competent cells in the treatment of malignant disease, Lancet 1:1054.PubMedGoogle Scholar
  422. Takita, H., Minowada, J., Han, T., et al., 1976, Adjuvant immunotherapy in bronchogenic carcinoma, Ann. N. Y. Acad. Sci. 277:345.PubMedGoogle Scholar
  423. Teimoorian, B., and McCune, W. S., 1963, Surgical management of malignant melanoma, Am. Surg. 29:515.Google Scholar
  424. Ter-Grigorov, V. S., and Irlin, I. S., 1968, The stimulating effect of complete Freund’s adjuvant on tumor induction by polyoma virus in mice and by Rous sarcoma virus in rats, Int. J. Cancer 3:760.PubMedGoogle Scholar
  425. Thienpont, D., Vanparijs, O. F. J., Raeymaekers, A. H. M., et al., 1966, Tetramisole (R-8299), a new, potent broad spectrum anthelmintic, Nature (London) 209:1084.Google Scholar
  426. Thiry, L., Goldberger, S., Tack, L., et al., 1977, Comparison of the immunogenicity of hamster cells transformed by adenovirus and herpes simplex virus, Cancer Res. (in press).Google Scholar
  427. Thomas, E. D., Storb, R., Clift, R. A., et al., 1975, Bone marrow transplantation, N. Engl. J. Med. 292:832.PubMedGoogle Scholar
  428. Thor, D. E., and Schlossman, S., 1969, Transfer of the cellular immune response in guinea pigs with RNA extracts, Fed. Proc. 28:629.Google Scholar
  429. Thorbecke, G. J., Friedman-Kien, A. E., and Vilcek, J., 1974, Effect of rabbit interferon on immune responses, Cell. Immunol. 11:290.Google Scholar
  430. Toujas, L., Sabolovic, D., Dazord, L., 1972, The mechanism of immunostimulation induced by inactivated Brucella abortus, Rev. Eur. Etud. Clin. Biol. 17:267.Google Scholar
  431. Townsend, C. M., Eilber, F. R., and Morton, D. L., 1976, Skeletal and soft tissue sarcomas, J. Am. Med. Assoc. 236:2187.Google Scholar
  432. Trainin, N., Berger, M., and Kaye, A., 1967, Some characteristics of a thymic humoral factor determined by assay in vivo of DNA synthesis in lymph nodes of thymectomized mice, Biochem. Pharmacol. 16:711.PubMedGoogle Scholar
  433. Trainin, N., Kook, A. I., Umiel, T., et al., 1975, The nature and mechanism of stimulation of immune responsiveness by thymus extracts, Ann. N. Y. Acad. Sci. 249:349.PubMedGoogle Scholar
  434. Tripodi, D., Parks, L. C., and Brugmans, J., 1973, Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer, N. Engl. J. Med. 289:354.PubMedGoogle Scholar
  435. Van Ghinckel, R. F., and Hoebeke, J., 1977, Effect of levamisole on spontaneous rosette-forming cells in murine spleen, Eur. J. Immunol. (in press).Google Scholar
  436. Veltman, L. L., Kern, D. H., and Pilch, Y. H., 1974 Immune cytolysis of human tumor cells mediated by xenogeneic immune RNA, Cell. Immunol. 13:367.PubMedGoogle Scholar
  437. Verhaegen, H., DeCree, J., DeCock, W., et al., 1973, Levamisole and the immune response, N. Engl. J. Med. 289:1148.Google Scholar
  438. Vetto, R. M., Berger, D. R., and Nolte, J. E., 1976, Transfer factor therapy in patients with cancer, Cancer 37:90.PubMedGoogle Scholar
  439. Vogler, W. R., and Chan, Y. K., 1974, Prolongation of remission in myeloblastic leukemia by Tice strain bacillus Calmette Guérin, Lancet 2:128.PubMedGoogle Scholar
  440. Vogler, W. R., Bartolucci, A. A., and Omura, G. A., 1977, A randomized clinical trial of BCG in myeloblastic leukemia conducted by the Southeastern Cancer Study Group, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  441. Wainberg, M. A., and Margolese, R. G., 1977, Desentization of effective anti-tumor immunity in guinea pigs, Eur. J. Med. (in press).Google Scholar
  442. Waldorf, D. S., Haynes, H. A., and Van Scott, E. J., 1967, Cutaneous hypersensitivity and desensitization to mechlorethamine in patients with mycosis fungoides lymphoma, Ann. Intern. Med. 67:282.PubMedGoogle Scholar
  443. Waldmann, T. A., Strober, W., and Blaese, R. M., 1972, Immunodeficiency disease and malignancy: Various immunological deficiencies of man and the role of immune processes in the control of malignant disease, Ann. Intern. Med. 77:605.Google Scholar
  444. Wanebo, H. J., Keneny, M., Pinsky, C. M., et al., 1976, Influence of poly-A poly-U on immune responses in cancer patients, Ann. N. Y. Acad. Sci. 277:288.PubMedGoogle Scholar
  445. Webb, D., Braun, W., and Plescia, O. J., 1972, Antitumor effect of polynucleotide and theophylline, Cancer Res. 32:1814.PubMedGoogle Scholar
  446. Weiss, D. W., 1976, MER and other mycobacterial fractions in the immunotherapy of cancer, Med. Clin. N. Am. 60:473.PubMedGoogle Scholar
  447. Weiss, D. W., 1977, Neoplastic disease and tumor immunology from the prospective of host parasite relationships, in: International Symposium on the Spontaneous Regression of Cancer, NCI Monograph, in press.Google Scholar
  448. Weiss, D. W., and Yashphe, D. J., 1973, Non-specific stimulation of anti-microbial and antitumor resistance and of immunological responsiveness by MER fraction of tubercle bacilli, in: Dynamic Aspects of Host Parasite Relationships, Vol. 1 (N. Zuckerman and D. W. Weiss, eds.), pp. 163–223, Academic Press, New York.Google Scholar
  449. Weiss, D. W., Bonhag, R. S., and Leslie, P., 1966, Studies on the heterologous immunogenicity of methanol insoluble fraction of attenuated tubercle bacilli BCG. II. Protection against tumor isografts, J. Exp. Med. 124:1039.PubMedGoogle Scholar
  450. Weiss, D. W., Stupp, Y., Manny, N., et al., 1975, Treatment of acute myelocytic leukemia (AML) patients with the MER tubercle bacillus fraction: A preliminary report, Transplant. Proc. 7:545.Google Scholar
  451. Weis, D. W., Kuperman, O., Fathallah, N., et al., 1976, Mode of action of mycobacterial fractions in antitumor immunity, Ann. N. Y. Acad. Sci. 276:536.Google Scholar
  452. Wepsic, H. T., Zbar, B., Rapp, H. J., et al., 1970, Systemic transfer of tumor immunity: Delayed hypersensitivity and suppression of tumor growth, J. Natl. Cancer Inst. 44:955.PubMedGoogle Scholar
  453. Wheelock, E. F., and Larke, R. P. B., 1968, Efficacy of interferon in the treatment of mice with established Friend virus leukemia, Proc. Soc. Exp. Biol. Med. 127:230.PubMedGoogle Scholar
  454. Whittaker, J. A., and Slater, A. J., 1977, The immunotherapy of acute myelogenous leukemia using intravenous BCG, in: Immunotherapy of Cancer: Present Status of Trials in Man (W. Terry and D. Windhorst, eds.), in press.Google Scholar
  455. Wilkinson, P. C., O’Neal, G. J., McInroy, R. J., et al., 1973, Chemotaxis of macrophages: The role of a macrophage-specific cytotoxan from anaerobic corynebacteria and its relation to immunopotentiation in vivo, CIVA Found. Symp. Immunopotentiation 18:120.Google Scholar
  456. Wilson, D. B., and Wecker, E. E., 1966, Quantitative studies on the behavior of sensitized lymphoid cells in vitro. III. Conversion of normal lymphoid cells to an immunologically active status with RNA derived from isologous lymphoid tissue of specifically immunized rats, J. Immunol. 47:512.Google Scholar
  457. Wollmark, N., and Fisher, B., 1974, The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice, Cancer Res. 34:2869.Google Scholar
  458. Woodruff, M. F. A., and Boak, J. L., 1966, Inhibitory effect of injection of Corynebacterium parvum on the growth of tumor transplants in isogenic hosts, Br. J. Cancer 20:345.PubMedGoogle Scholar
  459. Woodruff, M. F. A., and Dunbar, N., 1973, The effect of Corynebacterium parvum and other reticuloendothelial stimulants on transplanted tumors in mice, CIBA Found. Symp. Immunopotentiation 18:287.Google Scholar
  460. Woodruff, M. F. A., and Nolan, B., 1963, Preliminary observations on treatment of advanced cancer by injection of allogeneic spleen cells, Lancet 2:426.PubMedGoogle Scholar
  461. Woodruff, M. F. A., Dunbar, N., and Chaffar, A., 1973, The growth of tumors in T-cell deprived mice and their resonse to treatment with Corynebacterium parvum, Proc. R. Soc. London Ser. B 184:97.Google Scholar
  462. Wright, P. W., Hellström, K. E., Hellström, I., et al., 1976, Sera therapy of malignant disease, Med. Clin. N. Am. 60:607.PubMedGoogle Scholar
  463. Wybran, J., Levin, A. S., Spitler, L. E., and Fudenberg, H. H., 1973, Rosette-forming cells, immunological deficiency diseases, and transfer factor, N. Engl. J. Med. 288:710.PubMedGoogle Scholar
  464. Wybran, J., Levin, A. S., Fudenberg, H. H., et al., 1975, Thymosin effects in normal human blood T-cells, Ann. N. Y. Acad. Sci. 249:300.PubMedGoogle Scholar
  465. Yagel, S., Gallily, R., and Weiss, D. W., 1977, Effect of treatment of MER fraction of tubercle bacilli on hydrolytic lysozomal enzyme activity of mouse peritoneal macrophages, Cell. Immunol. 19:381.Google Scholar
  466. Yamamura, Y., Yoshizaki, K., Azuma, I., et al., 1975, Immunotherapy of human malignant melanoma with oil-attached BCG Cell. wall skeleton, Gann 66:355.PubMedGoogle Scholar
  467. Yamamura, Y., Azuma, I., Taniyama, T., et al., 1976, Immunotherapy of cancer with Cell. wall skeleton of Mycobacterium bovis bacillus Calmette Guérin, Ann. N. Y. Acad. Sci. 277:209.PubMedGoogle Scholar
  468. Yasuhara, S., Kimura, I., and Onoshi, T., 1974, Antitumor activity of peritoneal exudate cells of the mouse administered with OK432, Med. Biol. 89:375.Google Scholar
  469. Yron, I., Weiss, D. W., Robinson, E., Cohen, D., Adelberg, M. G., Mekori, T., and Haber, M., 1973, Immunotherapeutic studies in mice with the methanol extraction residue (MER) fraction of BCG: Solid tumors, Natl. Cancer Inst. Monogr. 39:33.PubMedGoogle Scholar
  470. Zbar, B., and Tanaka, T., 1971, Immunotherapy of cancer: Regression of tumors after intralesional injection of living Mycobacterium bovis, Science 172:271.Google Scholar
  471. Zbar, B., Bernstein, I. D., and Rapp, H. J., 1971, Suppression of tumor growth at the site of infection with living BCG, J. Natl. Cancer Inst. 46:831.PubMedGoogle Scholar
  472. Zbar, B., Bernstein, I. D., and Bartlett, G. L., 1972, Immunotherapy of cancer: Regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis, J. Natl. Cancer Inst. 49:119.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1977

Authors and Affiliations

  • Evan M. Hersh
    • 1
  • G. M. Mavligit
    • 1
  • J. U. Gutterman
    • 1
  • S. P. Richman
    • 1
  1. 1.Department of Developmental Therapeutics, M. D. Anderson Hospital and Tumor InstituteThe University of Texas System Cancer CenterHoustonUSA

Personalised recommendations